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We investigated the mechanism of toxicity and resistance development of small molecule 
tyrosine kinase inhibitor lapatinib in HCT 116 colon cancer cells. Lapatinib mediated cell 
death in HCT 116 cells was caspase independent and involved cytosolic release of 
apoptosis inducing factor. Treatment of HCT 116 cells with 10µM Lapatinib lead to the 
outgrowth of lapatinib resistant HCT 116 cells. Our studies show that alterations in the 
expression and activation of Bcl-2 family proteins allow lapatinib resistant HCT 116 cells 
to resist cytotoxic effects of lapatinib as well as of other commonly used 
chemotherapeutic agents.   
In hepatoma and pancreatic cancer cells, the effects of combining multi-kinase inhibitor 
sorafenib with histone deacetylase inhibitors (HDACIs) namely, vorinostat and sodium 
 xix
valproate were investigated. It was found that sorafenib synergizes with HDACIs 
resulting in enhanced cell death compared to death induced by the drugs individually. 
The mechanism of action of sorafenib and vorinostat combination treatment as well as 
sorafenib and sodium valproate combined treatment was shown to involve activation of 
the CD95 death receptor pathway. Alterations in the CD95 pathway can render cancer 
cells resistant to chemotherapeutic agents. Hence, we combined sorafenib+sodium 
valproate with a BH-3 domain mimetic named obatoclax (GX-15-070) which resulted in 
enhanced toxicity to cancer cells. More importantly, knock-down of CD95 (to mimic 
non-functional CD95 pathway) reduced cell death induced by sorafenib+sodium 
valproate combined but failed to protect cells from cell death induced by 
sorafenib+sodium valproate+obatoclax combined. This suggests that combining 
sorafenib+HDACI with obatoclax may not only enhance toxicity to cancer cells but may 
also reduce chances of resistance development via alterations in the CD95 pathway. 
These studies enhance our knowledge of existing treatment strategies for cancer as well 
as throw light on how current approaches can be improved in order to better diagnose and 
treat cancer. Understanding mechanisms of drug action as well as resistance development 
will allow us to combine existing therapies effectively in order best target cancer cells as 
well as provide us with information that can help us design new cancer treatment 
strategies. 
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GENERAL INTRODUCTION 
 
A. Hallmarks of cancer: 
Cancer is often defined as a disease involving uncontrolled division of abnormal cells. 
Cancer is one of the leading causes of death, with one in eight deaths worldwide resulting 
due to cancer (www.cancer.org(1)). In the United States, cancer is the second leading 
cause of death and it is estimated that in 2009, 1500 people will die everyday as a result of 
cancer (www.cancer.org(2)). 
 It is thought that a normal cell undergoes a series of changes in its genome that can 
eventually lead to the generation of an aberrant cancer cell. Hanahan and Weinberg 
identified six hallmarks of a cancer cell that are shared by most cancers (Hanahan D and 
Weinberg RA, 2000). 
1) No requirement for external growth signals  
2) Insensitivity to anti-growth signals 
3) Evasion of cell death signaling 
4) Infinite potential to replicate 
5) Ability to maintain oxygen and nutrient supply via angiogenesis  
6) Ability to invade tissue and metastasize 
There are a variety of growth factor receptors such as epidermal growth factor receptors 
(EGFR), platelet-derived growth factor receptor (PDGFR), insulin-like growth factor-1 
receptor (IGF-1R) and vascular endothelial growth factor receptor (VEGFR). Such 
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receptors and their ligands as well as a variety of transcription factors and cell death 
regulators are called oncogenes as mutant forms of these proteins or increased expression 
of these proteins can lead to transformation of a normal cell into a cancerous cell (Croce 
CM, 2008). 
Normal healthy cells have growth factor receptors that are activated upon binding 
stimulatory growth factors/ligands. Active receptors can mediate downstream signaling 
that can stimulate cell growth and proliferation. There are no known normal cells that can 
proliferate in the absence of such stimulatory signals (Hanahan D and Weinberg RA, 
2000). However, cancer cells have been known to be able to proliferate independent of 
such stimulatory signals. For instance, HCT 116 colon cancer cells are highly malignant 
and are growth factor independent. HCT 116 cells have one mutant allele of KRas with a 
Gly13Asp mutation. This mutation in KRas has been shown to be linked to up-regulation 
of epiregulin (a pan-ERBB ligand) since loss of mutant KRas leads to reduction in levels 
of epiregulin in HCT 116 cells (Yacoub A, et. al. 2006). This mutant KRas mediated up-
regulation of epiregulin has been shown to be invovled in promoting the tumorigenic 
potential of HCT 116 cells (Baba I, et. al. 2000). Other studies have shown that upon 
nutreint deprivation induced growth arrest, growth factor-dependent cells require both 
nutrients and growth factors to recover from growth arrest, where as HCT 116 cells require 
only nutrients to re-start DNA synthesis. This is because HCT 116 cells up-regulate 
transforming growth factor-alpha (TGF-α) via enhanced transcription which can activate 
EGFR and downstream pro-survival signaling even under growth arrest conditions. Hence, 
HCT 116 cells have a TGF-α autocrine loop that can allow constitutive EGFR activation 
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even under nutrient-deprivation and this allows them to be self sufficient in growth signals 
(Awwad RA, et. al. 2003). Other cancer cells have also been shown to have increased 
growth factor/ligand production due to altered gene expression resulting in an autocrine 
loop and hence aberrant activation of growth factor receptors and downstream signaling 
(Sizeland AM and Burgess AW. 1992).  
Growth factor receptors belonging to the EGFR family are tyrosine kinases and play an 
important role in cancer progression. They have been known to be over-expressed or 
mutated such that they are constitutively active in a variety of cancers and this can lead to 
increased activation of downstream pro-survival signaling resulting in aggressive cancer 
(Peschard, P. and Park, M. 2003; Sunpaweravong, P. et. al. 2005; Hynes NE and Lane HA. 
2005). These downstream pro-survival signaling pathways include the mitogen activated 
protein kinase (MAPK) pathway and the phosphotidyl inositol-3 kinase pathway (PI3K) 
(Grant S, et. al. 2002).  
B. The MAPK pathway: 
In order for MAPK signaling to occur downstream of EGFR activation, phosphorylated 
tyrosine residues on active EGFR are recognised by Src homology 2 domain containing 
scaffolding protein (SHC) which can hold growth factor receptor bound protein 2 (Grb2) in 
association with a guanine nucleotide exchange factor called son of sevenless (SOS) via its 
Src homoly 3 (SH3) domain. SOS assists activation of Ras protein (that is tethered to the 
cell membrane via farnesylation or genranylgeranylation) by allowing Ras to release 
guanosine diphosphate (GDP) in exchange for guanosine triphosphate (GTP) (Seabra MC. 
1998). There are three types of Ras proteins known to date – Harvey Ras (HRas), Kirsten 
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Ras (KRas), Neuroblastoma Ras (NRas) with KRas being the most frequently mutated Ras 
isoform in cancer (Downward J. 2003). Active Ras is thought to recruit Raf protein, a 
serine/threonine kinase also called a MAPkinase kinase kinase, to the cell surface. There 
are three types of Raf proteins known to exist namely, c-Raf-1, B-Raf and A-Raf with B-
Raf being the most commonly mutated form (Sridhar SS, et. al. 2005; Davies H, et. al. 
2002). Raf proteins exist in an inactive state, phosphorylated on certain residues and also 
bound to 14-3-3 protein (Sridhar SS, et. al. 2005). The mechanism involving Raf activation 
is not completely understood but it is thought that Ras-GTP is responsible for bringing Raf 
protein to the cell surface and interacting with it to alter its conformation assisting in Raf 
activation (Chong H, et. al. 2003). Some studies show that phosphatase enzymes such as 
protein phosphatase 2 (PP2) are known to dephosphorylate Raf on certain residues and 
allow it to be further phosphorylated on different residues by a Src family kinase rendering 
Raf in an active state (Jaumot M and Hancock JF. 2001; Alavi A, et. al. 2003). Active Raf 
can phosphorylate and activate mitogen-activated /extracellular-regulated protein kinase 
(MEK), also called MAPkinase kinase, which is a dual specificity kinase that can 
phosphorylate serine/threonine or tyrosine residues (Kyriakis JM, et. al. 1992; Dent P, et. 
al. 1992). Active MEK1/2 can activate MAPK called extracellular signal regulated kinase 
1/2 (ERK1/2) which is a serine/threonine kinase (Wu J, et. al. 1992). ERK1/2 can activate 
various proteins such as Fos, Myc and Cyclin D-1 that can result in cells entering the cell 
cycle (Birtwistle MR, et. al. 2007). ERK can phosphorylate and activate p90 ribosomal S6 
kinase or p90rsk which can phosphorylate transcription factors involved in cell 
proliferation (Amorino GP, et. al. 2002). ERK is also known to translocate into the nucleus 
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where it can phsophorylate and activate a variety of other proteins such as Elk-1, STAT 
proteins and the estrogen receptor (Whitmarsh AJ and Davis RJ. 1996; Adachi M, et. al. 
2000). ERK can phosphorylate and inhibit activation of caspase 9 and pro-apoptotic 
protein BAD (Allan LA, et. al. 2003; Scheid MP, et. al. 1999). The MAPK pathway can be 
aberrantly activated in cancer due to alterations in the upstream receptors (Nair PN, et. al. 
2001) or due to mutations in upstream Ras or Raf proteins rendering them constitutively 
active (Bakin RE, et. al. 2003; Pfister S, et. al. 2008). 
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Figure 1: The mitogen-activated protein kinase (MAPK) and the phosphotidyl 
inositol-3 kinase (PI3K) pathway 
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C. The p38 and JNK pathways: 
There are other MAP kinases such as p38 and c-Jun N-terminal kinase (JNK) (Davis RJ. 
2000). Four isoforms of p38 namely, α, β, γ and δ and three JNK proteins namely JNK 1, 2 
and 3 are known to date (Alonso G, et. al. 2000; Waetzig V and Herdegen T. 2005). Upon 
growth factor receptor activation, exposure to UV radiation, cytokines or mitogens, Ras 
and Rho family GTPases can lead to p38 and or JNK activation downstream (Johnson GL 
and Nakamura K. 2007). MEK 3 and MEK 6 can activate p38, MEK4 has been known to 
activate p38 and JNK where as MEK 7 solely activates JNK (Johnson GL and Nakamura 
K. 2007). Depending on cell type and stimulus, p38 and JNK signaling can promote cell 
growth and survival or it can enhance cell death signaling (Lamb JA, et. al. 2003; Thorton 
TM and Rincon M. 2009). For instance, depending on cell type and stimulus, p38 
activation can influence either the progression of cell cycle transition by phosphorylation 
of the retinoblastoma protein (pRb) or can lead to phosphorylation of the tumor suppressor 
p53 (which is often called “guardian of the genome” and is discussed in detail later) which 
can result in cell cycle arrest (Hoozemans JJ, et. al. 2004; Bulavin DV, et. al. 1999). p38 
activation has also shown to lead to mitogen-activated protein kinase-activated protein 
kinase 2 activation which can in turn activate HSP27. This pathway has been shown to be 
invovled in cellular invasion in prostate cancer (Xu L, et. al. 2006).  
It is thought that transient activation of JNK can mediate cell survival but prolonged 
activation of JNK can lead to cell death (Chen YR, et. al. 1996).  Also, studies from our 
laboratory have shown that JNK isoforms may have variable functions. Treatment of 
hepatocytes with deoxycholic acid lead to activation of JNK1/2 but it was found that under 
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this treament condition, JNK1 signaling was cytotoxic where as JNK2 signaling was 
cytoprotective (Qiao L, et. al. 2003).  
Activated JNK can translocate to the mitochondria where it has been known to be involved 
in the release of cytochrome c into the cytosol which is associated with activation of cell 
death pathways (Tournier C, et. al. 2000). Upon activation, JNK can also translocate to the 
nucleus and transactivate a variety of proteins including c-Jun, other transcription factors 
and can also promote apoptosis by increase the expression of pro-apoptotic genes 
(Dhanasekaran DN and Reddy EP). Reports show that in unstressed cells, JNK can lead to 
p53 ubiquitination and degradation (Fuchs SY, et. al. 1998). However, under certain 
stressful situations (such as upon DNA damage), JNK can phosphorylate and stabilize p53, 
preventing its degradation, and allowing p53 to initiate cell cycle arrest or cell death 
pathways (BuschmannT, et. al. 2001). Active JNK can phosphorylate pro-apoptotic protein 
BAD and allow this protein to engage in apoptotic signaling (Donovan N, et. al. 2002). 
The role of JNK in cell death pathways is consistent with JNK having a tumor suppressive 
role (Kennedy NJ and Davis RJ. 2003). However, other studies show that JNK has a 
preferential role in proliferation since JNK deficient mice were resistant to the induction of 
papillomas (Chen N., et. al. 2001). Secondly, it has been shown that mice harboring 
prostate cancer cells when treated with antisense JNK1 and JNK2 inhibited tumor growth 
and lead to significant tumor regression (Yang YM, et. al. 2003). Other reports show that 
JNK signaling is involved in the malignant transformation of osteoblasts and in the 
progression of osteosarcomas (Papachristou DJ, et. al. 2003). Hence, JNK is often thought 
to have a pro-oncogenic role.  
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Figure 2: p38 and JNK signaling pathways. 
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D. The PI3K pathway: 
The PI3K pathway can also mediate pro-survival signaling. PI3K is a dimer consisting of a 
p85 regulatory subunit and a p110 catalytic subunit (Cantley LC. 2002). Activation of 
receptor tyrosine kinases can recruit PI3K directly or via adaptor molecules (SHC-GRb2-
SOS complex) (Cantley LC. 2002). PI3K can then phosphorylate phosphotidylinositol 
bisphosphate (PIP2) to generate phosphotidylinositol trisphosphate (PIP3). PIP3 in turn 
can recruit signaling proteins with pleckstrin homology domain (PH domain) such as 
serine threonine kinases phosphoinositol-dependent kinase-1 (PDK-1) and Akt (also called 
protein kinase B) to the membrane (Luo J, et.al. 2003). This brings Akt and PDK1 in close 
proximity allowing them to interact resulting in PDK1 mediated Akt phosphorylation and 
activation (Lawlor MA and Alessi DR. 2001). Active Akt can then regulate a variety of 
proteins that control cell proliferation, survival, growth and other processes. For instance, 
Akt can inhibit the function of death-inducing proteins such as BAD and p53 and it can 
regulate cell cycle by stabilizing cyclin-D (Luo J, et.al. 2003). There are three known 
mammalian isoforms of Akt namely, Akt 1, 2 and 3 that are generated from distinct genes 
(Franke TF. 2008). Reports suggest that these isoforms of Akt have diverse functions (Bae 
SS, et. al. 2003; Jiang ZY, et. al. 2003). PTEN, a tumor suppressor and a negative 
regulator of the PI3K-Akt pathway can dephosphorylate PIP3 and convert it back to PIP2 
(Cantley LC and Neel BG. 1999). Certain cancers have been shown to have mutant PTEN 
such that it can no longer inhibit the PI3K pathway and thereby allow constant activation 
of this pro-survival pathway (Maehama T and Dixon JE. 1999). Other oncogenic changes 
that can lead to hyperactivity of the PI3K-Akt pathway are alterations in growth factor 
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receptors and Ras which are both upstream of Akt. Hyperactivity of the Akt pathway is 
regarded as a negative prognostic marker for disease outcome in cancer patients 
(LoPiccolo J, et. al. 2008). A mutation in the PH domain of Akt1 has also been associated 
with increased plasma membrane recruitment and activation of the kinase and its 
downstream pathways (Bleeker FE, et. al. 2008). Hence, the PI3K/Akt pathway has been a 
prime target in developing therapies to treat cancer. 
E. The tumor suppressor p53: 
As mentioned previously, p53 is often referred to as the “guardian of the genome”. Murine 
double minute 2 or MDM2 (HDM2 in humans) protein maintains p53 at low levels in 
normal, unstressed cells by ubiqitinating p53 and targeting it for degradation by the 
proteasome (Kubbuttat MH, et. al. 1997). Post translational modifications of p53 such as 
acetylation, phosphorylation and methylation also play a role in stabilizing and activating 
p53 under stressful situations (Moll UM and Petrenko O. 2003). Several stimuli such as 
hypoxia and DNA damage can activate enzymes such as ATM and ATR that can 
phosphorylate p53 thereby increasing its stability and transcriptional ability (Graeber TG, 
et. al. 1994; Siliciano JD, et. al. 1997). These enzymes can also rapidly increase p53 levels 
via phosphorylation of MDM2 that prevents it from interacting with p53 (Maya R, et. al. 
2001; Shinozaki T, et. al. 2003). p53 activation can in turn lead to increase in ARF protein 
levels which can interact with MDM2 and inhibit its p53-ubiqutin ligase activity there by 
allowing p53 to stabilize (Palmero I, et. al. 1998). On the other hand, p53 activation can 
increase transcription of the gene encoding for MDM2 which will eventually lead to 
inhibiton of p53 forming a negative feedback loop (Wagner J, et. al. 2005). In several 
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cancers with wild type p53, the MDM2 gene has been shown to be amplified (Oliner JD, 
et. al. 1992). Hence, in spite of bearing wild-type p53, the amplified MDM2 expression 
may prevent appropriate activation of p53 upon toxic insult to these cells thereby allowing 
them to evade cell death. In certain cancers, mutations or epigenetic alterations in the gene 
encoding for ARF have been noted which could also result in lack of appropriate p53 
response to prevent unwarranted cell growth and proliferation (Saporita AJ, et. al. 2007). 
Above mentioned alterations in MDM2 and ARF function can prevent appropriate p53 
activation there by assisting cancer cells in evading cell death pathways. 
Failure to arrest cell cycle progression can allow a cell with damaged DNA to replicate. 
p53 is known to regulate cell cycle check points in order to maintain the genetic stability of 
cells. Active p53 is known to mediate cell cycle arrest by inducing the transcription of p21 
which is a cyclin dependent kinase inhibitor (Miyashita T and Reed JC. 1995). Once 
active, p53 is also known to lead to the transcription of a variety of genes that encode 
proteins involved in cell death pathways such as BAX, Fas, Noxa, Puma, Caspase 1 and 6, 
Apaf-1, etc. These genes are expressed to similar levels during p53 mediated G1 arrest and 
apoptosis (Attardi LD, et. al. 2000). Depending on cell type and stimuli, activation of p53 
can result in not only apoptosis or cell cycle arrest but also in induction of differentiation 
or senescence (Vousden KH and Lu X. 2002). p53 mediated effects can also occur 
independent of its transcription activity. In the presence of stress, p53 is thought to initiate 
cell death pathways by translocating to mitochondria resulting in loss of mitochondrial 
membrane potential and activation of the caspase cascade (Marchenko ND, et.al. 2000; 
Nemajerova A, et.al. 2005). Reports suggest that mitochondrial migration of p53 has a 
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more important role to play in p53 mediated cell death than cell cycle arrest. Studies show 
that translocation of p53 to the mitochondria after exposure to stress occurs in cells that 
undergo cell death but not in cells that undergo cell cycle arrest (Marchenko ND, et.al. 
2000; Erster S, et. al. 2004). About 50% of cancers lack p53 protein expression, bear 
mutant or inactive p53 (Toledo F and Wahl GM. 2006). Mutation in p53 in germ line cells 
has also been implicated in Li-Fraumeni syndrome making patients prone to a variety of 
cancers (Senzer N, et. al. 2007). Mutant p53 can play an important role in the 
transformation of normal cells to cancerous cells and it is also known that tumors bearing 
wild type p53 are more sensitive to chemotherapy than tumors bearing mutant p53 (Wang 
W and El-Deiry WS. 2008). Most p53 mutations in cancer cells are missense mutations 
that occur in its DNA binding domain, precluding p53 from binding to its response 
elements on DNA and therefore preventing transcription of p53 target genes (Strano S, et. 
al. 2007; Hussain SP and Harris CC. 1998; Prives C and Hall PA. 1999). p53 bears a 
tetramerization domain and upon activation, this domain allows p53 proteins to tetramerize 
which is essential for p53 function, enabling p53 to bind DNA and transcribe genes. In 
cancer cells, mutations have been noted in the tetramerization domain of p53 that can 
prevent wild type p53 function by inhibiting p53 tetramer formation (Chène P. 2001). 
Mutations in tumor suppressor genes are recessive in nature and hence, in order for a cell 
to become cancerous, both alleles of the tumor suppressor gene need to be mutated. This 
theory is called “Knudson’s two hit hypothesis” and was suggested by Dr. Alfred Knudson 
in 1971 (Knudson A. 1971). p53 is an exception to this rule since mutant p53 can exert a 
“dominant negative” effect such that mutant p53 can inhibit the function of wild type p53 
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generated from the un-mutated allele by forming non-functional p53 tetramers that can not 
transcribe genes succesfully (Blagosklonny MV. 2000).  
Studies have also shown that certain cancer cells have p53 protein with gain of function 
mutations that allow mutant p53 to exert functions that the wild type protein can not. These 
mutants may not only behave as dominant negative mutants to inhibit wild type p53 
function but also provide a growth and survival advantage to the cancer cell as they have 
been implicated in increasing expression of genes such as the multi drug resistance gene 
which can prove to be very beneficial for cancer cells by allowing them to pump out toxic 
drugs from their systems (van Oijen M and Slootweg PJ. 2000; Chin KV, et. al. 1992). 
Cancers bearing a gain of function mutation in p53 indicate poorer prognosis than cancers 
with no p53 protein at all (Dittmer D, et. al. 1993).  
F. Cell death pathways: 
As discussed previously, the presence of cellular stress can lead to activation of cell death 
pathways. There are various types of cell death pathways such as autophagy, apoptosis and 
necrosis. Attempts have been made to reach a consensus on the criteria used to 
differentiate between these forms of death but have been unsuccessful partially due to 
overlaps in characteristics observed in these form of cell death (Krantic S, et. al. 2007).  
Autophagy (derived from Greek, “auto” meaning self and “phagy” meaning to eat) is a 
form of programmed cell death (Yorimitsu T and Klionsky DJ. 2005; Clarke PG. 1990). 
Autophagy has a role in protein degradation and cellular turnover and is characterized by 
sequestration of the cytosol and organelles in a multi-membrane vesicle which is then 
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degraded by the lysosomal system (Gozuacik D, Kimchi A. 2004). Autophagy usually 
occurs at a low basal level and is often upregulated during events such as starvation when 
the nutrient demands of a cell are not met (Kourtis N and Tavernarakis N. 2009). In such 
situations, autophagy can allow degradation of cytoplasmic components of a cell, there by 
providing the nutrient deprived cell with substrates for energy metabolism and protein 
synthesis in order to survive. However, there is an ongoing debate regarding the role of 
autophagy since it has not only been observed to be involved in survival processes but it 
has also been known to cause cell death (Levine B and Klionsky DJ. 2004; Shintani T and 
Klionsky DJ. 2004; Wang CW and Klionsky DJ. 2003; Bursch W. 2004).  
Apoptosis is a type of programmed cell death and cells undergoing apoptosis have a very 
characteristic morphology that includes membrane blebbing, cell shrinkage, chromatin 
condensation, nuclear and DNA fragmentation (Savill J, et. al. 2003). Necrosis is an un-
programmed form of cell death that occurs due to external insults on a cell or due to non-
physiological attacks such as ischemia, hypothermia or hypoxia (de Bruin EC and Medema 
JP. 2008). Necrosis is characterized by loss of membrane integrity, swelling of 
mitochondria and the cell itself resulting in cell lysis (de Bruin EC and Medema JP. 2008). 
It is generally accepted that necrosis is a process that does not require energy where as 
apoptosis is an ATP-dependent process (Leist M, et. al. 1997). Another difference between 
apoptosis and necrosis is that apoptosis occurs in individual cells whereas necrosis occurs 
in contiguous cells and also generates an immune response which is absent in apoptotic 
cell death (Vakkila J and Lotze MT. 2004). 
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Extrinsic and intrinsic death pathways are apoptotic cascades that can be activated by 
several chemotherapeutic agents. The extrinsic cell death pathway involves activation of 
death receptors that are members of the tumor necrosis factor receptor superfamily, known 
to regulate cell death and survival (Ashkenazi A. 2002). One of the best characterized 
death receptor is CD95, also called Fas or APO-1 receptor, which binds to CD95/Fas 
ligand (CD95L/FasL) (Walczak H and Krammer PH. 2000). Upon ligand binding, CD95 
death receptors can trimerizes and recruit adaptor molecules such as the Fas associated 
death domain (FADD) (Walczak H and Krammer PH. 2000). FADD can then recruit pro-
caspase 8 or pro-caspase 10 to the death receptor which leads to the formation of the death 
inducing signaling complex or DISC (Kischkel FC, et. al. 1995). Caspases are cystein 
proteases, synthesized as pro-enzymes and cleaved next to aspartate residues for activation 
after which they can act as death effector molecules for several cell death pathways 
(Degterev A, et. al. 2003). Once recruited by FADD to the death receptors, pro-caspases 
can become activated by undergoing cleavage and can further activate downstream 
caspases resulting in amplification of the caspase cascade (Degterev A, et. al. 2003; 
Scaffidi C, et. al. 1998). Once caspases are activated, they can lead to cleavage of various 
cytosolic and nuclear substrates such as cytoskeletal proteins and nuclear lamins that can 
lead to loss of cell shape and result in shrinking of the nucleus, respectively (Degterev A, 
et. al. 2003). Active caspases can also cleave the inhibitor of caspase activated DNAse 
(ICAD) leading to polynucleosomal DNA fragmentation resulting in the characteristic 
oligomeric DNA fragments seen upon caspase activation (Nagata S. 2000). Similar to 
various other signaling pathways, the extrinsic cell death pathway also can be negatively 
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regulated by FLIP proteins. There are several splice variants of FLIP known to exist at the 
mRNA levels but only three isoforms of FLIP protein namely, c-FLIP-s, c-FLIP-r and c-
FLIP-l  have been identified (Djerbi M, et. al. 2001; Rasper DM, et. al. 1998; Golks A, et. 
al. 2005). Studies have suggested similar roles of c-FLIP-s and c-FLIP-r in death receptor 
mediated apoptosis (Golks A, et. al. 2005). c-FLIP-s plays an anti-apoptotic role as it can 
inhibit the activation of pro-caspase 8 and there by inhibit CD95 induced cell death (Golks 
A, et. al. 2005). These FLIP proteins have sequence homology to caspase 8 but lack their 
catalytic domain and hence when FLIP is recruited to activated death receptors, it can 
block activation of the caspase cascade and the cell death cascade (Krueger A, et. al. 
2001). However, the role of c-FLIP-l in the activation of CD95 pathway remains 
controversial. Some studies suggest the c-FLIP-l is an anti-apoptotic molecule where as 
other studies ascribe pro-apoptotic functions to c-FLIP-l referring to its assistance in pro-
caspase 8 activation (Chang DW, et. al. 2003; Micheau O, et. al. 2002).  
Death receptors play an important role in immunity. T-cells can regulate the immune 
system via production of CD95L which can trigger cell death in neighboring target cells 
such as lymphocytes by activating the CD95 receptors in these cells (Krammer PH. 2000). 
However, if the T-cells secrete CD95L resulting in soluble CD95L, this can activate CD95 
receptors on their own cell membrane and can lead to their death (Klas C, et. al. 1993). 
Reports suggest that some cancers express CD95L but lose CD95 receptor expression. This 
can allow them to evade attack from host immune cells by killing tumor-attacking T-cells 
via activation of the CD95 receptors on these cells (Muschen M, et. al. 2000). Studies have 
shown that certain cancer cells that do express CD95 receptors can also evade attacks from 
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host immune cells by expressing soluble decoy receptor 3 (DcR3), known to compete with 
CD95 receptor for CD95L, thereby interfering with CD95 mediated cell death activation in 
cancer cells (Roth W, et. al. 2001). Down-regulation or absence of surface CD95 receptor 
expression in cancer cells can occur via epigenetic changes such as hypermethylation of 
gene promoters and can play an important role is mediating resistance to chemotherapeutic 
agents that require CD95 receptors to induce their toxic effects (van Noesel MM, et. al. 
2002; Friesen C, et. al. 1997). It has been suggested that the CD95 death receptor system 
has a tumor suppressive function due to the occurrence of CD95 receptor mutations in 
cancers (Fulda S and Debatin KM. 2006). Elevated FLIP expression has also been found in 
cancer cells that can render them resistant to chemotherapeutic agents requiring activation 
of the extrinsic cell death pathway to mediate their toxic effects (Longley DB, et. al. 2006).   
Activation of the intrinsic cell death pathway depends on the balance between pro-death 
and pro-survival Bcl-2 family proteins. The Bcl-2 family proteins have upto four Bcl-2 
homology (BH) domains (BH1, BH2, BH3 or BH4) (Yip KW and Reed JC. 2008). The 
pro-survival Bcl-2 proteins (such as Bcl-xl, Mcl-1, Bcl-2, etc.) have all four BH domains 
where as the pro-death members can be further divided into two classes: the “multi-
domain” proteins that have BH1, BH2 and BH3 domains (such as Bax, Bak and Bok) and 
the “BH3 only proteins” that, as the name suggests, bear only the BH3 domain (such as 
Bid, Bim, Bad, Puma, Noxa) (Yip KW and Reed JC. 2008; Reed JC. 2006; Strasser A. 
2005). Bcl-2 family members are known to interact with each other via the BH3 domain 
(Chittenden T, et. al. 1995).  
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The “BH3 only” proteins can interfere with the actions of pro-survival Bcl-2 family 
proteins and on the other hand, can also interact with Bak and Bax leading to their 
activation (A. Letai et. al. 2002). Studies suggest that oligomerization of pro-death 
members of the Bcl-2 family such as Bak and Bax can activate the intrinsic cell death 
pathway by forming pores in the outer mitochondrial membrane leading to mitochondrial 
outer membrane permeabilization (MOMP) (Chipuk JE and Green DR. 2008; Green DR 
and Kroemer G. 2004). Cells obtained from mice that do not express Bak and Bax fail to 
undergo cell death in response to insults that would typically lead to death in cells that 
express these proteins (Wei MC, et. al. 2001). Loss of mitochondrial membrane potential 
and MOMP can lead to release of various proteins from the inter-membrane space of the 
mitochondria that can induce cell death. These include proteins that can activate caspases 
(e.g. cytochrome c), proteins that can interfere with the function of caspase inhibitors (e.g. 
SMAC and Omi/Htra2 known to interfere with inhibitors of apoptosis or IAPs) and also 
proteins that are thought to cause cell death independent of caspase activation (e.g. 
apoptosis inducing factor and endonuclease G that can make their way to the nucleus 
where they can lead to DNA degradation) (Penninger JM and Kroemer G. 2003; Reed JC. 
2002). Cytochrome c release from the mitochondria can lead to caspase activation via 
formation of the apoptosome which consists of cytochrome c, apoptotic protease activating 
factor 1 (Apaf-1) and pro-caspase 9 (Cain K, et. al. 2000). Binding of cytochrome c to 
Apaf-1 is thought to facilitate ATP binding to the apoptosome which then allows for 
caspase 9 activation (Adrain C, et. al. 1999). Active caspase 9 can lead to activation of 
various other caspases including caspase 2, 3, 6, 7, 8 and 10 (Guerrero AD, et. al. 2008). It 
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is important to note that the extrinsic and intrinsic cell death pathways can crosstalk. As 
mentioned earlier, activated death receptors can lead to caspase 8 activation. Active 
caspase 8 can cleave Bid (a “BH3 only” protein) which can translocate to the mitochondria 
and interfere with the pro-survival functions of Bcl-xl and is also thought to play a role in 
assisting in oligomerization of Bak and/or Bax that leads to pore formation in the 
mitochondrial membrane and MOMP (Gross A, et. al. 1999; Korsmeyer SJ, et. al. 2000).  
Disruption of the intrinsic cell death pathway has been observed in cancer. For instance, 
over-expression of pro-survival Bcl-2 family proteins can promote oncogenesis (Tsujimoto 
Y, et. al. 1984; Fulda S and Debatin KM. 2006). Defects in the expression of pro-death 
Bcl-2 family members can also occur in cancer cells. Homozygous deletions and 
inactivating mutations have been identified in genes encoding for pro-death Bcl-2 family 
proteins in cancer cells which can prevent activation of cell death pathways and hence 
prove beneficial for cancer cell survival (Meijerink JP, et. al. 1998).  
G. Chemotherapeutic agents: 
The above mentioned pathways and proteins can play an important role in tumor 
development and progression. Hence, drugs have been developed to target them in order to 
treat cancer. As mentioned previously, receptor tyrosine kinases such as EGFR have been 
implicated in cancer progression as they have been found to be mutated such that they are 
constitutively activated or over-expressed in cancer (Peschard, P. and Park, M. 2003; 
Sunpaweravong P, et. al. 2005). Hence, several drugs have been developed to target these 
kinases. The development of small molecule tyrosine kinase inhibitors (TKIs) targeting 
EGFR family members was based on the observation that mutations in the ATP-binding 
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site affected receptor kinase function severely (Honegger AM, et. al. 1987). TKIs prevent 
ATP binding on the internal kinase domain of EGFR therefore preventing phosphorylation 
of key tyrosine residues which is an essential step in receptor activation (Imai K and 
Takaoka A. 2006). Gefitinib and erlotinib are two TKIs that inhibit ERBB1 receptors 
(Janne PA. 2008). Lapatinib was developed to target both ERBB1 and ERBB2 receptors of 
the EGFR family and targeting two tyrosine kinases is advantageous as it can be used to 
treat cancers that over-express ERBB1 and/or ERBB2 and also reduces the chances of 
resistance development in cancer cells (Yarden Y and Sliwkowski MX. 2001). Several 
monoclonal antibodies have been developed that recognize and bind to the extracellular 
domain of receptor tyrosine kinases thereby preventing ligand binding and downstream 
signaling (Rowinsky EK. 2004). Binding of monoclonal antibodies to receptors can 
induces dimerization and internalization of the receptor, eventually leading to receptor 
degradation and downregulation (Mendelsohn J. 2002). Herceptin/Trastuzumab is a 
monoclonal antibody that inhibits ERBB2 activation and has proven to be quite successful 
in treating breast cancers that frequently over-express ERBB2 receptors (Bange J, et. al. 
2001). 
In solid tumors, hypoxia can induce the release of vascular endothelial growth factor 
(VEGF) by tumor cells and by regions around the tumor called stroma (Das B, et. al. 
2005). VEGF can bind to its receptors (that are also tyrosine kinases) and can stimulate 
angiogenesis (Parikh AA and Ellis LM. 2004). Hence, VEGF inhibitors were developed to 
inhibit the remodelling of the network of blood vessels required by certain solid tumors for 
growth and survival. Some VEGFR inhibitors are: semaxinib, vatalinib and sutent.   
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Platelet derived growth factor receptors (PDGFR) are also receptor tyrosine kinases that 
have been implicated in cancer progression as they can mediate downstream pathways that 
can regulate cellular growth and proliferation (Sedlacek HH. 2000). PDGFR has been 
implicated in cellular transformation and has been found to be over-expressed in a variety 
of cancer cells (Sedlacek HH. 2000). Leflunomide is a PDGFR inhibitor that was 
developed to inhibit PDGFR mediated signalling in cancer cells (Shawver LK, et. al.1997).  
As mentioned previously, alterations in Ras oncogene have been implicated in cancer 
progression (Downward J. 2003). Ras is tethered to cell membranes via farnesylation or 
geranylgeranylation (Seabra MC. 1998). Hence, inhibitors of farnesyl transferase (e.g. FTI-
277) and geranylgeranyl transferase-1 (e.g. GGTI-298) have been developed to prevent the 
prenylation of Ras protein which is required for its activity (Der CJ and Cox AD. 1991).  
Active Raf, which is downstream of Ras, can mediate pro-survival signaling and has been 
frequently observed to be mutated in cancer cells (Davies H, et. al. 2002). Hence Raf 
kinase inhibitors such as sorafenib have been developed. However, it is now known that 
sorafenib can inhibit Raf as well as a variety of other kinases including VEGFR and 
PDGFR (Strumberg D, et. al. 2005).  
In tumor cells, over-expression of MDM2 can inhibit wild-type p53 activation protecting 
cancer cells from toxic effects of chemotherapeutic agents (Oliner JD, et. al. 1992). Hence, 
drugs such as Nutlins have been developed that can mimic p53 and thereby bind MDM2 
(Vassilev LT. 2005). Nutlins can therefore inhibit p53-MDM2 interaction and allowing 
appropriate activation of the p53 pathway in cancer cells leading to cell cycle arrest, cell 
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death and also growth inhibition of tumor cells in human tumor xenograft models 
(Vassilev LT, et. al. 2004).  
Histone deacetylase inhibitors (HDACI) are another family of chemotherapeutic agents 
that are thought to inhibit tumor survival and growth by regulating expression of several 
genes involved in proliferation and/or apoptosis (Peart MJ, et. al. 2005). Histone 
deacetylase inhibitors (HDACI) represent a class of agents that act by blocking histone de-
acetylation, thereby modifying chromatin structure and gene transcription. HDAC 
inhibitors (HDACIs) promote histone acetylation and neutralization of positively charged 
lysine residues on histone tails, allowing chromatin to assume a more open conformation, 
which favors transcription (Gregory PD, et. al. 2001). However, HDACIs are known to 
promote acetylation of non-histone proteins as well (Dasmahapatra G, et. al. 2007; Marks 
PA, et. al. 2003; Bali P, et. al. 2005; Kwon SH, et. al. 2002). Most HDACIs are thought to 
function by binding to the zinc atom in the HDAC catalytic site thereby inhibiting the 
enzyme’s activity (Richon VM. 2006; Taddei A, et. al. 2005). HDACI such as vorinostat 
and sodium valproate are known to cause up-regulation of pro-apoptotic genes, down-
regulation of anti-apoptotic genes, growth arrest, differentiation as well as cell death in a 
variety of cancer cells (Mitsiades CS, et. al. 2004; Richon VM, et. al. 1998; Kuendgen A, 
et. al. 2007).    
Certain cancer cells have been shown to be highly dependent on over-expression of pro-
survival Bcl-2 family proteins in order to evade death signals induced by chemotherapeutic 
agents (Tsujimoto Y, et. al. 1984). Hence, BH-3 mimetics were developed that mimic the 
BH-3 domain of the pro-death Bcl-2 family members and interact with pro-survival Bcl-2 
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members there by inhibiting their function (Zhang L, et. al. 2007). One such agent is ABT-
737 that has a high affinity for binding Bcl-xl, Bcl-2 and Bcl-w but since it is unable to 
effectively inhibit Mcl-1, several cancer cells have been shown to be resistant to this agent 
(van Delft MF, et. al. 2006). Another BH-3 mimetic is -(-) Gossypol that is known to 
inhibit Bcl-2, Bcl-xl and Mcl-1 and is currently in Phase II clinical trials for treatment of 
prostate cancer (Meng Y, et. al. 2008). Gossypol can induce a conformational change in 
Bcl-2 and Bcl-xl proteins thereby converting their pro-survival function to pro-death 
resulting in cytochrome c release from the mitochondria that can induce cell death 
pathways (Lei X, et. al. 2006). Obatoclax is another such BH-3 mimetic that is currently in 
Phase II clinical trials being investigated both as a single agent and in combination with 
other drugs (www.geminx.com).  
Hence, new molecular targets are being discovered and novel drugs as well as drug 
combinations are being identified that may enhance our ability to treat as well as prevent 
resistance development in cancer. 
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MECHANISM OF LAPATINIB TOXICITY AND RESISTANCE IN HCT 116 
CELLS 
 
A. Introduction: 
The EGFR family consists of four members, namely ERBB1, ERBB2, ERBB3 and 
ERBB4 (Olayioye, et. al. 2000; Yarden Y and Sliwkowski MX. 2001). These receptors are 
present on the cell surface as monomers and upon ligand binding, can homo- or hetero-
dimerize thereby increasing their affinity for ATP binding which allows 
autophosphorylation of specific tyrosine residues on the cytosolic domain of the receptors 
that serve as docking sites for molecules which can mediate downstream intracellular 
signaling (Hynes NE and Lane HA. 2005; Lin NU and Winer EP. 2004; Nelson MH and 
Dolder CR. 2006). A variety of cancers have been shown to have deregulated EGFR 
signaling via various mechanisms such as constitutive receptor activation, impaired 
receptor down-regulation and increased receptor stimulation via an autocrine loop leading 
to constitutive downstream pro-survival signaling resulting in very aggressive tumors 
(Peschard, P. and Park, M. 2003; Sizeland AM and Burgess AW. 1992; Sunpaweravong P, 
et. al. 2005; Salomon, DS, et. al. 1995; Hynes NE and Lane HA. 2005). Hence, studies 
have been performed to identify mechanisms via which ERBB receptors and their 
downstream signaling pathways can be inhibited in such tumor cells. Current strategies 
aimed at inhibiting receptor activation include (i) monoclonal antibodies that prevent 
ligand binding to the receptors (example: cetuximab), (ii) quinazoline-derived small 
molecule tyrosine kinase inhibitors (TKIs) that prevent ATP binding in the kinase domain 
of the receptors thereby inhibiting receptor kinase activity required to activate downstream 
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signaling (example: lapatinib, erlotinib) and (iii) dominant negative ERBB1 and ERBB2 
receptors (CD533 and CD572, respectively) that have truncated C-terminal kinase 
domains, hence forming non-functional dimers with wild type receptors (Imai K and 
Takaoka A. 2006; Schmidt-Ullrich RK, et. al. 2003). 
Lapatinib is a reversible small molecule TKI developed by GlaxoSmithKline that can 
efficiently inhibit ERBB1 and ERBB2 activation. IC50 values for purified ERBB1 and 
ERBB2 inhibition via lapatinib are 10.2 and 9.8 nM, respectively (Wood ER, et. al. 2004; 
Rusnak DW, et. al. 2001). Several studies show lapatinib to be a promising therapeutic 
agent for treating cancer. Lapatinib (Tykerb) was recently approved by the Food and Drug 
Administration to be used in combination with capecitabine to treat patients with advanced 
or metastatic breast cancer that over-express ERBB2 and have been previously treated with 
other drugs (National Cancer Institute). Lapatinib has been studied in 
herceptin/trastuzumab resistant breast cancer lines and has been shown to induce apoptosis 
in such cells by inhibiting downstream pro-survival signaling mediated by ERBB1, 
ERBB2 and also insulin like growth factor –1 receptor (IGF-1R) (Nahta R, et. al. 2007). 
Bcl-2 is an anti-apoptotic protein that has been shown to be over-expressed in certain 
cancer cells and associated with drug resistance by allowing cells to evade death signals 
(Reed JC, et. al. 1996; McDonnell TJ, et. al. 1992). Combination studies involving 
lapatinib and Bcl-2 inhibitors in certain cancer cells show synergistic anti-tumor effects 
(Witters LM, et. al. 2007). Lapatinib is >300 fold selective for ERBB1 and ERBB2 
inhibition compared to its ability to inhibit other kinases commonly found in a cell 
(Rusnak DW, et. al. 2001). This high selectivity may prevent undesirable effects arising 
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from non-specific inhibition of other molecules by lapatinib. Lapatinib is a particularly 
efficacious anti-cancer agent because it can inhibit two ERBB receptors simultaneously. 
This may allow lapatinib to be used to treat a wide variety of cancers that may depend on 
ERBB1 and/or ERBB2 signaling and also reduce the chances of resistance development in 
cancer cells.  
Usually, cancer patients treated with chemotherapeutic agents respond well initially 
resulting in the reduction of tumor size and death of cancer cells. However, months or 
years later, the cancer can reappear as an aggressive and therapeutically refractory 
malignancy that may be cross-resistant to many other therapeutic drug treatments, making 
such refractory cancers very difficult to manage (Kobayashi S, et. al. 2005). There are 
several ways in which a cancer cell can become resistant to chemotherapeutic agents. 
Resistance to trastuzumab has been suggested to be mediated via the insulin like growth 
factor –1 receptor (IGF-1R) signaling that can activate downstream pro-survival pathways 
(Lu Y, et. al. 2001; Camirand A, et. al. 2002). Src (a tyrosine kinase) and estrogen receptor 
have also been implicated in mediating resistance to TKIs in certain cancer cells by 
activating pro-survival signaling pathways (Qin B, et. al. 2006; Xia W, et. al. 2006). 
Resistance to ERBB targeted drugs can also occur due to mutations in ERBB receptors 
resulting in the inability of drug to inhibit receptor activation (Pao W, et. al. 2005; Sok JC, 
et. al. 2006). Multi-drug resistance pumps may also be involved in drug resistance by 
pumping out toxic drugs from cancer cells (Szakacs G, et. al. 2006). As mentioned 
previously, studies have also shown that certain cancer cells over-express anti-apoptotic 
molecules belonging to the Bcl-2 family which can protect these cells from cyto-toxic 
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effects of drugs by allowing them to evade cell death signals and hence render them 
resistant to chemotherapeutic agents (Raffo AJ, et. al. 1995).  
Constitutive activity of the transcription factor nuclear factor κB (NF-κB) has also been 
implicated in drug resistance (Herrmann JL, et. al. 1997; Sumitomo M, et. al. 1999). 
Inhibitor of κB (IκB) usually sequesters NF-κB in the cytosol. IκB Kinase (IKK) can 
phosphorylate IκB leading to its degradation. This releases NF-κB which can then 
translocate to the nucleus where it can initiate transcription of genes involved in survival 
(Baldwin AS. 2001). In certain cancer cells, constitutive NF-κB activation due to defective 
IκB activity or persistent IKK activity, allows constant transcription of genes involved in 
cellular growth (Cabannes E, et. al. 1999; Kordes U, et. al. 2000).  
Resistance to the effects of lapatinib has been demonstrated in BT474 breast cancer cells 
and was reported to occur via estrogen receptor signaling (Xia W, et. al. 2006). As noted 
by the authors, a combination of lapatinib and estrogen receptor inhibitors may decrease 
the probability of development of refractory cancers and therefore enhance the chances of 
patient survival. Lapatinib has not been approved for the treatment of colon cancer yet, 
although its potential effectiveness has been reported. Various colon cancer cell lines have 
been reported to express ERBB1 and ERBB2 receptors, including HCT116 cells and 
lapatinib has been shown to cause inhibition of cell proliferation and apoptosis in vitro and 
in vivo in cancer cells of this origin (Cunningham MP, et. al. 2006; Zhou Y, et. al. 2006).  
We have generated lapatinib resistant HCT 116 colon cancer cells and the aim of this 
project was to understand the mechanism of action of lapatinib as well as lapatinib 
resistance in HCT116 colon cancer cells. Understanding drug resistance may enable us to 
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reduce the chances of occurrence of refractory cancers by targeting the pathways utilized 
by resistant cells for survival and increase the likelihood of patient survival.   
B. Materials: 
Dulbecco's modified Eagle's medium, penicillin/streptomycin, and 0.25% trypsin-EDTA 
were purchased from Invitrogen (Carlsbad, CA). HCT116 cells were originally purchased 
from American Type Culture Collection (Manassas, VA) before multiple transfection 
procedures. Fetal bovine serum was purchased from Hyclone (Logan, UT). Trypan blue 
dye and crystal violet for colony-formation assays were purchased from Sigma-Aldrich (St. 
Louis, MO). For Western blot analysis, 8 to 16% Tris-HCl gels were used (Bio-Rad 
Laboratories, Hercules, CA). CMV control virus, ERBB1-CD533, and ERBB2-CD572 
were obtained from Dr. Kristoffer Valerie (Virginia Commonwealth University, 
Richmond, VA). BCL-XL recombinant adenovirus was obtained from Dr. J. Moltken 
(University of Cincinnati, Cincinnati, OH). Dominant-negative (dn) dnI B (S32A) 
recombinant adenovirus and STAT inhibitory peptide were purchased from Cell Biolabs 
(Philadelphia, PA) and Calbiochem, respectively. Control siRNA and siRNA to 
knockdown apoptosis-inducing factor (AIF) (SI02662114, SI02662653), Bcl-xl 
(SI03025141, SI03068352, SI03112018, SI00023191), Mcl-1 (SI02781205, SI00131768), 
and BAK (SI00299376, SI02654512) were purchased from QIAGEN (Valencia, CA). 
Lapatinib was obtained from GlaxoSmithKline (Boston, MA). The IGF-1R inhibitor PPP, 
the Src family kinase inhibitor PP2, 4-hydroxy tamoxifen, and epidermal growth factor 
were purchased from Calbiochem (San Diego, CA). Primary antibodies against Mcl-1, Bcl-
xl, BAX, BAK, AIF, and cytochrome c were purchased from Cell Signaling Technology 
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Inc. (Danvers, MA). ERBB1 (Ab-5) antibody for fluorescence microscopy, primary 
antibody for active BAK (Ab-1), caspase 8 inhibitor LEHD, caspase 9 inhibitor IETD, and 
pan-caspase inhibitor zVAD were purchased from Calbiochem. EGF receptor (Ab-13 
cocktail) and c-ERBB2 (Ab-11 cocktail) to immunoprecipitate ERBB1 and ERBB2 were 
purchased from NeoMarkers (Freemont, CA). Anti-Phospho-Tyr 4G10 antibody was 
purchased from Millipore Bioscience Research Reagents (Temecula, CA). Primary 
antibodies for GAPDH, wild-type p53 (FL-393), mutant p53 (Pab 240), ERK2, active BAX 
(6A7), and protein A/G Plus agarose beads for immunoprecipitation were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Secondary mouse antibody (Alexa Fluor 680 
goat anti-mouse IgG) was purchased from Invitrogen, and secondary rabbit antibody (anti-
rabbit IgG) was purchased from Rockland Immunochemicals (Gilbertsville, PA). UCN-01 
was kindly supplied by was provided by the Cancer Treatment and Evaluation Program of 
the National Cancer Institute. VP-16 was purchased from Sigma. 
C. Methods: 
Cell culture: Parental HCT116 colon cancer cells (WT cells) were cultured in DMEM 
media containing 5% fetal bovine serum and 1% Penicillin/Streptomycin. Lapatinib 
resistant HCT116 cells (WT-AD cells) were cultured in DMEM media containing 5% fetal 
bovine serum, 1% Penicillin/Streptomycin and 2µM Lapatinib. When WT-AD cells were 
thawed out of the freezer, they were plated in DMEM media containing 5% fetal bovine 
serum, 1% Penicillin/Streptomycin and 10µM Lapatinib for 3 days to ensure they were 
Lapatinib resistant.  
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Detection of Cell Death by Trypan Blue Assay: After treatment, medium was removed 
and cells were washed in 1X PBS. Cells were then harvested by trypsinization with 
Trypsin/EDTA for 5 min at 37°C. Because some apoptotic cells detached from the culture 
substratum into the medium, these cells were also collected by centrifugation of the 
medium at 1400 RPM for 5 min. The pooled cell pellets were resuspended and mixed with 
trypan blue dye. Trypan blue stain, in which blue dye-incorporating cells were scored as 
being dead, was performed by counting of cells using a light microscope and a 
hemacytometer. The number of dead cells was counted and expressed as a percentage of 
the total number of cells counted. 
Culture of Cells and Drug Treatments for Colony Formation Assays: Cells were 
plated (250–1000 cells/well of a 6-well plate). 12 h after plating medium was removed and 
serum-free medium was added to the cells for 24 or 48 h as indicated. After this, the serum-
free media was carefully removed and fresh media (with serum) was added. Colony 
formation assays were cultured for an additional 8-10 days, after which the media were 
removed, cells were fixed with methanol, stained with crystal violet, and counted manually. 
Immunoprecipitation and Western Blotting: 12 hours after plating cells, they were 
either infected with CD533 and CD572  or control virus for 24h or serum starved and 
treated with indicated concentrations of lapatinib or dimethyl sulfoxide (DMSO) for 2h. 
After either of these treatments, cells were treated with 20ng/ml EGF or vehicle for 10 
mins. Cells were then scraped using RIPA buffer (50mM Tris HCl pH 7.4, 150mM NaCl, 
1%NP-40, 1% Sodium Deoxycholate, 1mM PMSF, 1mM Sodium orthovanadate, 10mM 
Sodium Fluoride, 10mM β-glycerophosphate, 0.5mM EGTA, 0.5mM EDTA and protease 
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inhibitor cocktail purchased from (Roche)) and ERBB1 or ERBB2 was 
immunoprecipitated as indicated, after which samples were boiled for 10 minutes in whole 
cell lysis buffer (0.5 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 
0.02% bromophenol blue). 12 hours after plating cells, they were also scraped using a non-
denaturing lysis buffer (50mM Tris HCl pH 7.4, 150mM NaCl, 1%NP-40, 0.1% sodium 
deoxycholate, protease and phosphatase inhibitor cocktails (Roche)) and mutant p53 was 
immunoprecipitated after which samples were boiled for 10 min in whole cell lysis buffer. 
Cells were also scraped in CHAPS buffer (10mM HEPES, 140mM NaCl, 1% CHAPS) and 
then active BAK or active BAX was immunoprecipitated. Samples were boiled for 10 min 
in whole cell lysis buffer. All samples were then loaded on 8%-16% Criterion pre-cast gels 
(BIORAD) after normalizing total protein and run for about 2 hours. Proteins were then 
electrophoretically transferred onto 0.22um nitrocellulose membranes and immunoblotted 
with various primary antibodies as indicated.  
Virus Infections: Cells were infected 12h after plating with adenoviruses at an 
approximate multiplicity of infection of 30 for 4 h with gentle rocking, after which time the 
media was replaced. Cells were further incubated for 24 h to ensure adequate expression of 
transduced gene products before drug exposures. 
Transfection of Cells with Small Interfering RNA Molecules: RNA interference for 
down-regulating the expression of AIF, Mcl-1, Bcl-xl and BAK was performed using 
validated target sequences designed by Qiagen. For transfection, 20-40 nM concentration 
of the annealed siRNA-targeting AIF, Mcl-1, Bcl-xl or BAK, or the negative control (a 
"scrambled" sequence with no significant homology to any known gene sequences from 
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mouse, rat, or human cell lines) were used. The siRNA molecules were transfected into 
cells according to the manufacturer's instructions. Cells were cultured for 24 h after 
transfection before any additional experimentation. 
Cell Fractionation: 12h after plating cells, they were serum starved and treated with 2µM 
lapatinib or DMSO for 36h. This experiment was performed on ice at all times. Medium 
from plates was then aspirated and cells were scraped in buffer (75mM 
NaCl+8mMNa2HPO4+1mMNa2H2PO4+0.5mMEDTA+ 0.5mMEGTA with freshly added 
350ug/ml digitonin, 250mM sucrose, protease and phosphatase inhibitor cocktails (Roche)) 
and passed through a 25 gauge needle 12 times. After 15 to 30 minutes on ice, cells were 
spun down at 5000RPM for 1.5 minutes at 4oC to remove cell debris. Pellet was discarded 
and supernatant was transferred to a new tube and spun down at 13000 RPM for 25 
minutes at 4oC. The supernatant obtained is the cytosolic fraction where as the pellet is the 
mitochondrial fraction. Whole cell lysis buffer was added to the supernatant and the pellet, 
boiled for 10 minutes and then western blot analysis was performed. This protocol was 
adapted from Leist M, et. al. (1998). 
Flow Cytometry:  Flow cytometric analysis of cells was performed after staining by the 
the ANNEXIN V-FITC kit (Beckman Coulter) according to the manufacturer’s 
instructions and read on Beckton Dickinson FACScan.  
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D. Results:  
Generation of Lapatinib resistant HCT116 cells: HCT116 colon cancer cells (henceforth 
called WT cells) were cultured in the presence of 10µM lapatinib, a concentration that is 
below the lapatinib Cmax in patients (GlaxoSmithKline). Within 72 h of lapatinib treatment, 
many cells became detached and died from this drug exposure. Cells were cultured in the 
presence of 10µM lapatinib for a further ~3 months until a homogeneous population of 
cells grew out from the survivors that were resistant to lapatinib (henceforth called WT-
AD cells). 
Confirmation of Lapatinib resistance in WT-AD cells: 24 h after plating WT and WT-AD 
cells, they were serum-starved and exposed to increasing concentrations of lapatinib (0-10 
µM) for 48 h. Trypan blue analysis showed that at each concentration of lapatinib tested, 
WT-AD cells showed significantly lower levels of cell death compared to WT cells (Figure 
3). The level of cell death observed in WT-AD cells treated with 10 µM lapatinib, which 
was the highest concentration of lapatinib used in this experiment, was comparable to the 
level of cell death observed in WT cells that were simply serum-starved (i.e. no lapatinib 
was added). Also, WT-AD cells were significantly protected from serum-starvation 
induced cell death compared to WT cells. This indicates that compared to WT cells, WT-
AD cells are resistant to lapatinib as well as serum-starvation.  
In another experiment, WT and WT-AD cells were serum-starved and exposed to vehicle 
or 2µM lapatinib for varying times (12 h – 48 h) and cell viability was measured by 
Annexin-PI staining flow cytometric analysis. Results confirmed that WT-AD cells were 
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resistant to the effects of 2µM lapatinib as well as serum-depletion compared to WT cells 
at each time point tested (Figure 4).  
WT and WT-AD cells were treated with either vehicle or increasing doses of lapatinib 
(0.1-10µM) without serum-starvation. Annexin-PI flow cytometric analysis showed that 
WT-AD cells were more resistant to the cyto-toxic effects of lapatinib at all doses tested 
compared to WT cells even in the presence of serum (Figure 5). 
Reinforcing our previous observations, colony formation assays showed that WT-AD cells 
are more resistant to the effects of serum-starvation than WT cells (Figure 6). Colony 
formation assays also showed that ionizing radiation reduced survival by comparable 
levels in both WT and WT-AD cells (Figure 7).  
Culturing WT-AD cells in the absence of lapatinib: To investigate whether lapatinib 
resistant WT-AD cells maintained their resistant phenotype if cultured in the absence of 
lapatinib, these cells were cultured without lapatinib for >10 flask passages (~2 months) 
and are labeled WT-AD10. Cell death levels in serum-starved WT-AD10 cells were not 
significantly different than the levels in serum-starved WT-AD cells under vehicle as well 
as lapatinib treated conditions. WT-AD and WT-AD10 cells showed much lower cell death 
levels compared to WT cells under serum starved conditions in the presence of vehicle or 
2µM lapatinib. Hence, WT-AD10 cells maintained their resistance to serum-starvation as 
well as lapatinib in spite of being cultured in the absence of the drug (Figure 8).   
Effect of chemotherapeutic agents on WT and WT-AD cells: To determine whether WT-
AD cells were cross-resistant to toxicity induced by commonly used chemotherapeutic 
agents, WT-AD and WT cells were treated with other chemotherapeutic agents namely, 
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VP-16 (etoposide), UCN-01 (an analogue of staurosporine) and Taxotere. WT-AD cells 
were significantly more resistant to all of these agents than parental WT cells at all doses 
tested (Figure 9 and 10).  
Effect of lapatinib on ERBB1 receptor activation: Next we wanted to determine whether 
lapatinib was able to inhibit ERBB1 receptor activation in WT and WT-AD cells. 
Increasing concentrations of lapatinib (0-2μM) resulted in increased inhibition of basal and 
epidermal growth factor (EGF) induced ERBB1 tyrosine phosphorylation in WT and WT-
AD cells (Figure 11). This confirmed that lapatinib was able to inhibit ERBB1 receptor 
activation in both cell lines and that lack of lapatinib uptake in WT-AD cells was not the 
mode of resistance in these cells. It was also noted that total ERBB1 levels in WT and WT-
AD cells were comparable as judged by immunoblotting of whole cell lysates.  
Cell surface ERBB1 receptor level in WT and WT-AD cells: Results from the previous 
experiment showed that basal and EGF stimulated levels of ERBB1 receptor tyrosine 
phosphorylation in WT-AD cells appeared to be lower compared to WT cells. Also, EGF 
mediated ERK1/2 phosphorylation in WT-AD cells was observed to be reduced compared 
to WT cells (Figure 11).  These data suggested that there may be fewer cell surface ERBB1 
receptors available for activation in WT-AD cells compared to WT cells. To investigate 
this possibility, immunocytochemistry was performed to look at the cell surface level of 
ERBB1 receptors in non-permeabilized, serum-starved WT and WT-AD cells. Results 
indicated that WT-AD cells appeared to have considerably lower plasma membrane 
associated ERBB1 levels compared to WT cells which could possibly explain why basal 
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and EGF induced ERBB1 phosphorylation appeared to be lower in WT-AD cells than in 
WT cells (Figure 12).  
VEGFR and c-KIT levels are comparable in WT and WT-AD cells: Over-expression of 
other growth factor receptors such as VEGFR-1 and c-KIT has been implicated in 
mediating resistance to chemotherapeutic agents (Bianco R, et. al. 2008; Raspollini MR, 
et. al. 2004). Immunoblotting analysis showed that levels of VEGFR-1 and c-KIT receptor 
were similar in WT and WT-AD cells and hence unlikely to be responsible for mediating 
lapatinib resistance in WT-AD cells (Figure 13).  
Role of Src, IGF-1R, estrogen receptor (ER), NF-κB or STAT in mediating lapatinib 
resistance: Since previous studies have implicated Src and IGF-1R in mediating drug 
resistance we wanted to investigate whether these kinases were important in mediating 
lapatinib resistance in WT-AD cells (Qin B, et. al. 2006; Lu Y, et. al. 2001). Inhibition of 
neither Src family kinases using the inhibitor PP2 nor IGF-1R function using the inhibitor 
PPP restored lapatinib sensitivity in WT-AD cells (Figure 14). It is noteworthy that 
inhibition of the IGF-1R with PPP caused significant toxicity in parental WT cells that was 
abolished in WT-AD cells. These data suggested that Src and IGF-1R were not primary 
mediators on lapatinib resistance in WT-AD cells. 
Previous studies have also implicated ER, NF-κB and STAT proteins in mediating drug 
resistance in cancer cells (Xia W, et. al. 2006; Herrmann JL, et. al. 1997; Sumitomo M, et. 
al. 1999; Catlett-Falcone R, et. al. 1999). Hence, we wanted to determine whether any of 
these proteins played a role in mediating lapatinib resistance in WT-AD cells. Incubation 
of WT-AD cells with ER inhibitor 4-hydroxy tamoxifen in phenol-red free media, 
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inhibition of NF-κB function by over-expression of IκB super-repressor (dominant 
negative IκB) or inhibition of STAT function by expression of STAT inhibitory peptide 
did not restore lapatinib sensitivity in WT-AD cells (Figure 15). In control studies, it was 
noted that expression of super-repressor IκB or STAT inhibitory peptide suppressed 
reporter construct activity in WT and WT-AD cells and in phenol red-free media, basal 
estrogen receptor activity was reduced by tamoxifen treatment in both WT and WT-AD 
cells (Figure 16). These control studies confirmed that super-repressor IκB, STAT 
inhibitory peptide and 4-hydroxy tamoxifen were functional. 
Role of multi-drug resistance (MDR) pumps in mediating lapatinib resistance: Since 
studies have shown that MDR pumps can mediate drug resistance in cancer cells, 
immunoblotting was performed to determine whether MDR pumps had a role to play in 
mediating lapatinib resistance in WT-AD cells (Szakacs G, et. al. 2006). Little change was 
observed in the levels of MRP-1, ABCG-2 and Pgp transporters in WT and WT-AD cells 
suggesting that these MDR pumps were not major players in mediating lapatinib resistance 
in WT-AD cells (Figure 17).  
Levels of pro- and anti-apoptotic proteins in WT and WT-AD cells: Alterations in the 
levels of Bcl-2 family members have been shown to mediate drug resistance in cancer cells 
(Raffo AJ, et. al. 1995; Tsujimoto Y, et. al. 1984; Fulda S and Debatin KM. 2006; 
Meijerink JP, et. al. 1998). To investigate this possibility in WT-AD cells, immunoblotting 
studies were performed which indicated that compared to WT cells, WT-AD cells 
expressed higher levels of p53 as well as anti-apoptotic Bcl-2 family proteins namely, Mcl-
1 and Bcl-xl (Figure 18). Over-expression of Bcl-xl abolished lapatinib toxicity on WT 
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cells (Figure 19).  WT-AD cells expressed lower levels of pro-apoptotic protein BAX 
compared to WT cells (Figure 18). Further, immunoprecipitation studies showed that upon 
treatment with lapatinib, WT-AD cells have reduced BAK and BAX activation compared 
to WT cells (Figure 18). This occurred in spite of the observation that total BAK levels 
appeared to increase in WT-AD cells, post lapatinib treatment.  
In WT-AD cells, knockdown of Mcl-1 expression, to a greater extent than that of Bcl-xl, 
partially reverted lapatinib resistance by ~50% compared to WT cells treated with lapatinib 
(Figure 20). In WT-AD cells, knockdown of BAK activation significantly reduced the 
reversion of their resistant phenotype due to Mcl-1 knock-down (Figure 21). 
Role of p53 in lapatinib resistance: Previous immunoblotting data indicated that WT-AD 
cells showed less p53 phosphorylation under vehicle or lapatinib treated conditions 
compared to WT cells. This is important since phosphorylation has been shown to play an 
important role in stabilizing and activating p53 so that it can elicit an appropriate response 
to cellular stress (Jimenez GS, et. al. 1999). Also, WT-AD cells have higher total p53 
levels than WT cells. It is known that in cancer cells, p53 expression is often elevated 
when p53 is mutated (Kohler MF, et al. 1992). Hence, we wanted to further investigate 
whether p53 in WT-AD cells was mutated. Native p53 proteins were immunoprecipitated 
from WT and WT-AD cells using an antibody that specifically recognizes mutant forms of 
p53, as judged by the recognition of mutant p53 tertiary structure within the DNA binding 
domain of p53. The p53 proteins were then separated on denaturing SDS-PAGE and 
immunoblotted. WT-AD cells, but not WT cells, immunoprecipitated “mutant” p53 
(Figure 22). Total mRNA was isolated from WT and WT-AD cells, amplified and 
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sequenced using primers specific for the DNA binding domain of p53. We noted, however, 
that a mutation in the p53 DNA binding domain was not detected in WT-AD cells. Further 
experiments will be required to investigate the role of p53 in WT-AD cells. 
Co-expression of dominant negative ERBB1 and ERBB2 to mimic lapatinib treatment: 
In order to investigate the mechanism of lapatinib mediated cell death, dominant negative 
ERBB1 and ERBB2 receptors were expressed in WT and WT-AD cells. Co-expression of 
dominant negative ERBB1 (CD533) and dominant negative ERBB2 (CD572) proteins 
inhibited both basal and EGF mediated ERBB1 and ERBB2 tyrosine phosphorylation in 
WT cells (Figure 23A). In spite of inhibiting ERBB1 and ERBB2 tyrosine phosphorylation 
similar to lapatinib, trypan blue analysis showed that co-expression of CD533 and CD572 
failed to recapitulate the toxic effects of lapatinib in serum-starved WT and WT-AD cells 
suggesting that lapatinib mediated cell death may involve mechanisms in addition to/other 
than inhibition of the ERBB receptor system (Figure 23C). Also, in WT cells, the lack of 
increased cell death in the presence of CD533 and CD572 was not due to the inability of 
these dominant negative receptors to inhibit survival pathways downstream of ERBB 
receptors as shown by their capability to inhibit ERK1/2 and AKT phosphorylation (Figure 
23B).  
Role of caspases in lapatinib mediated cell death: In WT cells, it was noted that inhibition 
of caspase enzymes resulted in protection from cell death induced by serum starvation 
(Figure 24). However, inhibition of caspase 8 or caspase 9 or treatment with a pan-caspase 
inhibitor did not protect WT cells from lapatinib mediated cell death (Figure 25). This 
indicated that lapatinib mediated cell death was likely caspase independent. As calpains, 
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cathepsins and serine proteases can also initiate cell death pathways, we wanted to 
investigate whether they were involved in lapatinib mediated cell death (Vandenabeele P, 
et. al. 2005; Droga-Mazovec G, et. al. 2008; Broker LE, et. al. 2004).  Inhibition of 
calpains, cathepsins and serine proteases did not protect WT cells from lapatinib toxicity 
suggesting that they were not likely involved in lapatinib mediated cell death (Figure 26 
and 27).  
Caspase independent mechanism of lapatinib mediated cell death: Since previous 
experiments suggested that lapatinib mediated cell death was likely caspase independent, 
we wanted to investigate the role of apoptosis inducing factor (AIF) as it is thought to 
initiate cell death pathways independent of caspase enzymes (Penninger JM and Kroemer 
G. 2003). Immunoblotting and cell fractionation studies showed that increased cytosolic 
release of AIF as well as cytochrome c was observed in WT cells treated with lapatinib but 
not in WT-AD cells under the same conditions (Figure 28). Knockdown of AIF expression 
reduced lapatinib toxicity in WT cells, and knockdown of AIF expression combined with 
pan-caspase inhibition further reduced lapatinib toxicity in these cells (Figure 29).  
 
 
 
 
 
 
 
 42
 
 
 
0
20
40
60
80
100
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
48h
Pe
rc
en
ta
ge
 c
el
l d
ea
th
V
eh
ic
le
0.
1μ
M
 L
ap
at
in
ib
0.
3μ
M
 L
ap
at
in
ib
0.
6μ
M
 L
ap
at
in
ib
1μ
M
 L
ap
at
in
ib
2μ
M
 L
ap
at
in
ib
3μ
M
 L
ap
at
in
ib
10
μM
 L
ap
at
in
ib
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
W
T
W
T-
A
D
Pe
rc
en
ta
ge
 c
el
l d
ea
th
V
eh
ic
le
0.
1μ
M
 L
ap
at
in
ib
0.
3μ
M
 L
ap
at
in
ib
0.
6μ
M
 L
ap
at
in
ib
1μ
M
 L
ap
at
in
ib
2μ
M
 L
ap
at
in
ib
3μ
M
 L
ap
at
in
ib
10
μM
 L
ap
at
in
ib
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: WT-AD cells are resistant to effects of lapatinib and serum-starvation. 
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated 
and 24 h after plating were grown in serum-depleted medium in the presence or absence of 
vehicle (DMSO) or lapatinib (0–10µM). Cells were isolated 48 h after 
serum-starvation/lapatinib addition, and cell viability was determined by trypan blue 
exclusion assay. Significant effects of lapatinib dose and cell type were observed (Two-
way ANOVA p < 0.0001, n=6). Bonferroni’s post-test revealed that under vehicle treated 
conditions and at each concentration of lapatinib tested, there was significantly higher cell 
death in WT cells compared to WT-AD cells (p < 0.0001). Data (mean ± S.E.M.) are from 
two independent experiments combined. 
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Figure 4: WT-AD cells are resistant to effects of lapatinib. 
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated 
and 24 h after plating were grown in serum-depleted medium in the presence or absence of 
vehicle (DMSO) or 2µM lapatinib. Cells were isolated at the indicated times, and cell 
viability (indicated under each panel) was determined by annexin-PI flow cytometric 
analysis (n=6). Data (mean ± S.E.M.) are from two independent experiments combined. 
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Figure 5: WT-AD cells are resistant to effects of lapatinib  
24 h after plating parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-
AD), they were treated with vehicle (DMSO) or increasing concentrations of lapatinib(0.1-
10μM). 48 h later, cells were isolated and cell viability (indicated under each panel) was 
determined by annexin-PI flow cytometric analysis (n=6). Data (mean ± S.E.M.) are from 
two independent experiments combined.  
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Figure 6: WT-AD cells are resistant to serum-starvation. 
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated 
as single cells and 12 h after plating were placed into serum-depleted medium for either 24 
or 48. Colonies were permitted to form over the following 10 to 14 days in fresh media 
with serum and no lapatinib, after which the media were removed, the colonies fixed and 
stained with crystal violet, and the colonies of >50 cells were counted. Significant effect of 
serum starvation duration was observed in both cell lines (p < 0.0001, Two-way ANOVA, 
n=8) and Bonferroni’s post test revealed that 48 h after serum starvation, WT cells showed 
significantly decreased survival than WT-AD cells (p < 0.05). Data (mean ± S.E.M.) are 
from two independent experiments combined. 
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Figure 7: Ionizing radiation affects WT and WT-AD cell survival. 
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated 
as single cells in sextuplicate and 12 h after plating were exposed to ionizing radiation (0-
3Gy). Colonies were permitted to form over the following 10 to 14 days, after which the 
media were removed, the colonies fixed and stained with crystal violet, and the colonies of 
>50 cells were counted. A significant effect of radiation dose in both cell lines (p < 0.0001, 
Two-way ANOVA, n=8) but no significant difference in the cell types was observed. Data 
(mean ± S.E.M.) are from two independent experiments combined.  
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Figure 8: Absence of lapatinib in culture does not restore lapatinib sensitivity in WT-
AD cells. Parental HCT116 cells (WT), HCT116 lapatinib-resistant cell (WT-AD) and 
HCT116 lapatinib-resistant cells that had been grown for ~2 months in the absence of 
lapatinib (WT-AD10) were plated and 24 h after plating were grown in serum-depleted 
medium in the presence or absence of vehicle (DMSO) or lapatinib (2µM). Cells were 
isolated 48 h after serum starvation/lapatinib addition, and cell viability was determined in 
triplicate by trypan blue exclusion assay. Student’s t-test showed that there was no 
significant difference between cell death levels in WT-AD and WT-AD10 cells under 
vehicle or lapatinib treated conditions. Data (mean ± S.E.M.) are from two independent 
experiments combined. 
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Figure 9: WT-AD cells are resistant to effects of VP-16 and UCN-01. 
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were treated 
with increasing concentrations of VP-16 (0-3μM) or UCN-01 (0-3μM).  36 h later, cell 
viability was determined by trypan blue exclusion assay. For both experiments effects of 
dose and cell type were observed (Individual Two-way ANOVA, p < 0.0001, n=6). 
Bonferroni’s post test revealed higher levels of cell death in WT cells relative to WT-AD 
cells under vehicle conditions and with VP-16 and UCN-01 treatment at all concentrations 
tested.  
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Figure 10: WT-AD cells are resistant to effects of Taxotere. 
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were treated 
with increasing concentrations of Taxotere (0-300nM).  48 h later, cell viability was 
determined by trypan blue exclusion assay. An effect of dose and an effect of cell type 
were observed (Two-way ANOVA, p < 0.0001, n=6). Bonferroni’s post test revealed that 
with increasing concentration of Taxotere, significantly higher level of cell death was 
observed in WT cells compared to WT-AD cells under each condition. Data (mean ± 
S.E.M.) are from two independent experiments combined. 
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Figure 11: Lapatinib inhibits ERBB1 and ERBB2 phosphorylation in WT and WT-
AD cells. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) 
were plated and 24 h after plating were grown in serum-depleted medium for 2 h followed 
by treatment with vehicle (DMSO) or lapatinib (L, 0–2 μM), as indicated. Thirty minutes 
after lapatinib exposure, cells were treated as indicated with 20 ng/ml EGF. Ten minutes 
after EGF addition, cells were harvested and subjected to lysis, and portions of the lysate 
either were immunoprecipitated to isolate ERBB1 and determine ERBB1 tyrosine 
phosphorylation or were directly subjected to SDS-PAGE to determine total ERBB1, 
GAPDH and ERK2 expressions and ERK1/2 phosphorylation. A representative study is 
shown (n = 2). 
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Figure 12: WT-AD cells appear to have fewer cell surface ERBB1 receptors than WT 
cells. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were 
plated and 24 h after plating were grown in serum-depleted medium for 2 h. Cells were 
fixed but not permeabilized, and cell surface levels of ERBB1 were determined by 
immunostaining and examination under fluorescent light microscope. Two representative 
images from one experiment are shown. Quantitative assessment of increase in 
fluorescence intensity was determined from fifty cells counted over two independent 
experiments.  
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Figure 13: No change in VEGFR and c-KIT receptor levels in WT-AD cells. 
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) 
were plated and 24 h later were lysed and lysate was subjected to SDS PAGE followed by 
immunoblotting to determine the expression of c-KIT and VEGFR-1 receptors as well as 
ERK2 as a loading control. 
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Figure 14: Lapatinib resistance in WT-AD cells is unlikely to be mediated via Src or 
IGF-1R. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) 
were plated and 24 h later were grown in serum-depleted medium with vehicle (DMSO), 
Lapatinib (2μM), PP2 (10μM), PPP (250nM), or the drug combinations indicated. Cells 
were isolated 48 h after serum starvation, and cell viability was determined trypan blue 
exclusion assay. Data (mean ± S.E.M.) are from two independent experiments combined. 
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Figure 15: Lapatinib resistance in WT-AD cells is unlikely to be mediated via 
estrogen receptor, NFκB or STAT. A) Parental HCT116 cells (WT) and HCT116 
lapatinib-resistant cells (WT-AD) were plated and 24 h after plating were grown in serum-
depleted, phenol red-free medium in the presence or absence of vehicle (DMSO), 4-
hydroxytamoxifen (4-OH TAM, 50 nM) or lapatinib (2μM); B) HCT116 lapatinib resistant 
cells (WT-AD) were plated and 12 h after plating were infected with either a control empty 
vector adenovirus or a recombinant adenovirus to express dominant-negative IκB (dnIκB). 
24 h after virus infection, cells were grown in serum-depleted medium in the presence or 
absence of vehicle (DMSO) or lapatinib (0–3μM). Cells were isolated 48 h after drug 
addition, and cell viability was determined by trypan blue exclusion assay; C) HCT116 
lapatinib-resistant cells (WT-AD) were plated and 12 h after plating were infected with 
either a control empty vector adenovirus or a recombinant adenovirus to express dominant 
negative STAT3 (dnSTAT3). 24 h after virus infection, cells were grown in serum-
depleted medium in the presence or absence of vehicle (DMSO) or lapatinib (3μM). Cells 
were isolated 48 h after drug addition, and cell viability was determined by trypan blue 
exclusion assay. Data (mean ± S.E.M.) are from two independent experiments combined. 
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Figure 16: Tamoxifen, STAT IP and dn IκB inhibit reporter construct activity in WT 
and WT-AD cells. 24 h after plating HCT116 cells (WT) and HCT116 lapatinib-resistant 
cells (WT-AD) in triplicate, they were infected with vector control virus (CMV), a virus to 
express dominant negative IκB (dnIκB), or treated with STAT3 inhibitory peptide (STAT 
IP). 24h later, cells were transfected with plasmids to express firefly luciferase under 
NFκB or STAT promoter regulation, respectively, together with an internal control renilla 
luciferase plasmid under constitutive expression. Parallel triplicate sets of plates of WT 
and WT-AD cells in phenol red free media were plated and 24 h later were transfected to 
express firefly luciferase under an estrogen responsive element (ERE), together with an 
internal control renilla luciferase plasmid under constitutive expression. 24 h later, cells 
were treated with Vehicle (VEH, DMSO) or 4-Hydroxy-tamoxifen (TAM, 50nM). 
Promoter activity for ERE, STAT and NFκB elements was measured 24 h aftr 
transfection/tamoxifen addition and corrected for transfection efficiency using the renilla 
luciferase plansmid ±S.E.M. (n=3). *, p < 0.05 less than corresponding vehicle 
control/vector control value (Student’s t-test). 
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Figure 17: Lapatinib resistance in WT-AD cells is unlikely to be mediated via MDR 
pumps. 24 h after plating HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-
AD), they were serum-starved for 24 h. Cells were then isolated and cell lysates were 
subjected to SDS PAGE followed by immunoblotting to determine the expression of 
MRP1, Pgp and ABCG2. Loading controls (GAPDH and EF1) were also measured. As a 
positive control for Pgp, lysates from doxorubicin resistant SW480 cells was included. 
Data from representative study (n=2).  
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Figure 18: Alterations in protein levels in WT-AD cells. Parental HCT116 cells (WT) 
and HCT116 lapatinib-resistant cells (WT-AD) were plated and 24 h later were grown in 
serum-depleted medium in the presence or absence of vehicle (DMSO) or lapatinib (2μM). 
Cells were isolated 48 h after lapatinib addition and were subjected to SDS-PAGE to 
determine the expression of multiple proteins. Or, cell were isolated 36 h after serum 
depletion/lapatinib addition, cells were isolated for immunoprecipitation to determine the 
amount of the activated forms of BAX and BAK. Representative images shown (n=2).  
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Figure 19: Bcl-xl over-expression protects WT cells from effects of lapatinib. Parental 
HCT116 cells (WT) were plated and 12 h after plating were infected with either a control 
empty vector adenovirus or a recombinant adenovirus to express BCL-XL. 24 h after virus 
infection, cells were grown in serum depleted medium in the presence or absence of 
vehicle (DMSO) or lapatinib (2μM). Cells were isolated 48 h after drug addition, and cell 
viability was determined by trypan blue exclusion assay. One-way ANOVA (n=6) revealed 
that lapatinib induced significantly high cell death compared to all other conditions (p < 
0.0001) and over-expression of BCL-xl significantly protected WT cells from cell death 
under both basal (p < 0.05) and laptinib treated conditions (p < 0.0001). Data (mean ± 
S.E.M.) are from two independent experiments combined. 
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Figure 20: Knockdown of Mcl-1 partially reverted lapatinib resistance in WT-AD 
cells. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were 
plated and 12 h later as indicated were transfected with siRNA molecules to reduce the 
expression of nothing/control (siSCR), Bcl-xl (siBcl-xl), or Mcl-1 (siMcl-1). 48 h after 
transfection, cells were grown in serum-depleted medium in the presence or absence of 
vehicle (DMSO) or Lapatinib (2μM) as indicated. Cells were isolated 36 h after serum 
starvation, and cell viability was determined by trypan blue exclusion assay. $, p < 0.05 
greater than corresponding HCT116 siSCR + lapatinib cell value (Student’s t-test, n=2). 
Data (mean ± S.E.M.) are from two independent experiments combined. 
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Figure 21: In WT-AD cells, knockdown of BAK reduced reversion of resistant 
phenotype due to Mcl-1 knock-down. HCT116 lapatinib-resistant cells (WT-AD) were 
plated and 12 h later as indicated were transfected with siRNA molecules to reduce the 
expression of nothing/control (siSCR), MCL-1 (siMCL-1), BAK (siBAK), or MCL-1 and 
BAK (siMCL+siBAK). Forty-eight hours after transfection, cells were grown in serum-
depleted medium in the presence or absence of vehicle (DMSO) or lapatinib (2 µM). Cells 
were isolated 48 h after serum starvation, and cell viability was determined by trypan blue 
exclusion assay. One-way ANOVA (n=6) with Bonferroni’s post test revealed that 
lapatinib induced significantly higher level of cell death compared to vehicle treated cells, 
knock-down of MCL-1 further significantly enhanced lapatinib lethality compared to all 
other conditions, knock-down of BAK significantly reduced lapatinib mediated cell death 
(p < 0.001) and knock-down of BAK and MCL-1 simultaneously not only prevented 
lapatinib mediated cell death (p < 0.001) but also reverted MCL-1 mediated enhancement 
of lapatinib induced cell death (p < 0.001). Data (mean ± S.E.M.) are from two 
independent experiments combined. 
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Figure 22: “Mutant” p-53 immunoprecipitated in WT-AD cells. Parental HCT116 cells 
(WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated and 24 h after plating 
were lysed and prepared for immunoprecipitation and pseudoimmunoprecipitation with or 
without mixing with agarose beads against mutated inactive p53 followed by SDSPAGE. 
The mixing with or without agarose beads was to ensure as a control that no spurious 
effects were observed on the SDS-PAGE mobility of p53 due to agarose bead inclusion in 
the loading of the gel. The SDS-PAGE was transferred to nitrocellulose and probed with 
an anti-p53 antibody and an anti-GAPDH antibody. Two representative images shown 
from three separate studies. 
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Figure 23: Dominant negative ERBB1 and ERBB2 fail to produce lapatinib like cell 
death levels in WT cells. A) Parental HCT116 cells (WT) were plated and 12 h after 
plating were infected with either a control empty vector adenovirus (CMV) or recombinant 
adenoviruses to express dominant-negative ERBB1-CD533 and dominant negative 
ERBB2-CD572. 24 h later, cells were grown in serum-depleted medium for 2 h and then 
treated with 20 ng/ml EGF as indicated for 10 min. Cells were isolated and subjected to 
immunoprecipitation of ERBB1 or ERBB2 followed by SDS-PAGE as indicated followed 
by anti-phospho-tyrosine blotting to determine the activation of ERBB1/2 proteins. A 
representative study is shown (n = 3). B) CD533 and CD572 also inhibit basal ERK and 
AKT phosphorylation. A representative study is shown (n = 2). C) 12 h after plating WT 
and WT-AD cells, they were infected with CMV, CD533, CD572 or both CD533 and 
CD572. 24h later, cells were grown in serum-depleted medium. Cells were isolated 48 h 
after serum starvation, and cell viability was determined by trypan blue exclusion assay. 
No significant effect on cell death was observed in either cell line under each condition 
tested (One-way ANOVA). Data (mean ± S.E.M.) are from two independent experiments 
combined. 
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Figure 24: Inhibition of caspases protects WT cells from serum starvation induced 
death. Parental HCT116 cells (WT) were plated and 24 h later were grown in serum-
depleted medium. Cells were isolated 48 h after serum-starvation and cell viability was 
measured by trypan blue exclusion assay. Cells were significantly protected from the 
effects of serum starvation in the presence of IETD (caspase 8 inhibitor), LEHD (caspase 9 
inhibitor) and ZVAD (pan-caspase inhibitor) (p < 0.0001, One-way ANOVA, n=6). Data 
(mean ± S.E.M.) are from two independent experiments combined. 
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Figure 25: Inhibition of caspases fails to protect WT cells from effects of lapatinib. 
Parental HCT116 cells (WT) were plated and 24 h later were grown in serum-depleted 
medium in the presence or absence of vehicle (DMSO) or lapatinib (2μM). In parallel, 
cells were grown in the presence or absence of vehicle (DMSO), the caspase 8 inhibitor 
IETD (50μM), the caspase 9 inhibitor LEHD (50μM) or the pan-caspase inhibitor zVAD 
(50μM). Cells were isolated 36 h after serum starvation, and cell viability was determined 
in triplicate by trypan blue exclusion assay. One-way ANOVA with Bonferroni’s post test 
revealed that WT cells were not protected from lapatinib induced cell death under any 
condition (p > 0.05, n=6). Data (mean ± S.E.M.) are from two independent experiments 
combined. 
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Figure 26: Inhibition of calpains and/or cathepsins fails to protect WT cells from 
effects of lapatinib. HCT116 cells (WT) were plated and treated with vehicle or lapatinib 
in combination with Cathepsin B and/or Calpain inhibitors. 24 or 36 h after treatment, cell 
viability was measured using trypan blue exclusion assay (n=6). Data (mean ± S.E.M.) are 
from two independent experiments combined. 
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Figure 27: Inhibition of serine proteases fails to protect WT cells from effects of 
lapatinib.  HCT116 cells (WT) were plated and treated with vehicle or lapatinib in 
combination with serine protease inhibitor, AEBSF. 48 h after treatment, cell viability was 
measured using trypan blue exclusion assay (n=6). Data (mean ± S.E.M.) are from two 
independent experiments combined. 
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Figure 28: Cytosolic AIF and cytochrome c release observed in WT cells treated with 
lapatinib. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) 
were plated and 24 h after plating were grown in serum-depleted medium in the presence 
or absence of vehicle (DMSO) or lapatinib (2μM). 36 h after serum depletion/lapatinib 
addition, cells were isolated for cell fractionation assay to determine AIF and cytochrome c 
release into the cytosol. A representative from two separate studies is shown. 
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Figure 29: Knock-down of AIF expression in WT cells reduces lapatinib toxicity. 
Parental HCT116 cells (WT) were plated and 12 h later as indicated were transfected with 
siRNA molecules to reduce the expression of nothing/control (siSCR) or AIF (siAIF). 48 h 
after transfection, cells were grown in serum-depleted medium in the presence or absence 
of vehicle (DMSO), lapatinib (2μM), in parallel with or without pan-caspase inhibitor 
zVAD (50μM), as indicated. Cells were isolated 36 h after serum starvation, and cell 
viability was determined by trypan blue exclusion assay. *, p < 0.05 less than 
corresponding siSCR cell value; #, p < 0.05 less than parallel siSCR value (Student’s t-test, 
n=6). Data (mean ± S.E.M.) are from two independent experiments combined. 
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E. Discussion: 
Development of resistance to chemotherapeutic agents is a common occurrence in the 
clinic (Kobayashi S, et. al. 2005). This study investigated the mode of lapatinib action as 
well as the mechanism of lapatinib resistance in HCT 116 colon cancer cells. We have 
shown that resistance to lapatinib is possible in colon cancer cells using cell viability as 
well as cell survival assays. These studies show that lapatinib resistant HCT 116 (WT-AD) 
cells are indeed resistant to lapatinib and also to serum-starvation (Figure 3, 4, 5, 6). It is 
known that refractory cancers are difficult to manage since often times they are not only 
resistant to the primary drug that was used to treat the cancer but also to other 
chemotherapeutic agents (Kobayashi S, et. al. 2005). To investigate whether this was true 
in the case of WT-AD cells, we treated WT (parental HCT116 cells) and WT-AD cells 
with various chemotherapeutic agents. Results showed that as expected, WT-AD cells 
were significantly more resistant to other chemotherapeutic agents that we tested, namely, 
UCN-01, VP-16 and Taxotere compared to WT cells (Figure 9,10). Another important 
finding was that the presence of lapatinib in the culture medium of WT-AD cells was not 
essential to maintain their lapatinib resistant phenotype (Figure 7). This shows that 
removal of lapatinib from the culture media of WT-AD cells does not restore lapatinib 
sensitivity in these cells.  
Studies have shown that one of the mechanisms by which cells can become resistant to 
ERBB tyrosine kinase inhibitors is by outgrowth of cells that have a mutation in the 
tyrosine kinase domain such that the inhibitor can no longer bind to the receptor (Pao W, 
et. al. 2005; Sok JC, et. al. 2006). Our studies show that lapatinib is able to inhibit basal 
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and EGF stimulated levels of ERBB1 receptor phosphorylation in both WT and WT-AD 
cells (Figure 11). This suggests that it is unlikely that a mutation in the ERBB1 receptor, 
such that it can no longer bind lapatinib, is the mechanism of lapatinib resistance in WT-
AD cells. These results also indicate that lapatinib intake is not disrupted in WT-AD cells 
and hence is not a mode of lapatinib resistance in these cells. It was noted that in spite of 
total ERBB1 levels in the two cell types being similar, both basal and EGF stimulated 
levels of ERBB1 receptor phosphorylation in WT-AD cells appeared to be lower compared 
to WT cells (Figure 11). To investigate the reason behind this observation, 
immunocytochemistry studies were performed to look at cell surface levels of ERBB1 
receptors available for activation in non-permeabilized WT and WT-AD cells under 
serum-starved conditions. Results showed that WT-AD cells appeared to have a lower cell 
surface ERBB1 receptor level than WT cells (Figure 12). Hence, this can also explain why 
EGF treatment resulted in a lower level of ERK1/2 phosphorylation in WT-AD cells 
compared to WT cells.  
Studies have shown that resistance to ERBB receptor inhibitors can occur due to over-
expression of other receptors and tyrosine kinases that can also mediate pro-survival 
signals (Lu Y, et. al. 2001; Camirand A; Qin B, et. al. 2006; Xia W, et. al. 2006). Vascular 
endothelial growth factor receptors (VEGFR) are known to play a major role in regulating 
cell cycle in certain cells and VEGFR-1 has been found to be over-expressed in certain 
cancer cells (Huang Y, et. al. 2007; Bianco R, et. al. 2008). c-KIT receptors are also 
known to play a role in cell survival, proliferation and differentiation pathways and 
increased expression of this receptor in certain cancers has been linked to poor patient 
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prognosis (Taniguchi M, et. al. 1999; Mcintyre A, et. al. 2005). To determine whether 
over-expression of VEGFR-1 or c-KIT receptors accounted for resistance to lapatinib in 
WT-AD cells, receptor expression levels were measured in WT and WT-AD cells. Results 
showed that there was no obvious difference in the expression levels of VEGFR-1 or c-
KIT receptors between WT and WT-AD cells (Figure 13). This suggested that lapatinib 
resistance was not likely due to altered expression of these receptors. 
In some cell types, including colon cancer cells, Src family nonreceptor tyrosine kinases 
and the insulin-like growth factor-1 receptor tyrosine kinase (IGF-1R) have been linked to 
drug resistance (Lu Y, et. al. 2001; Camirand A, et. al. 2002; Xia W, et. al. 2006). Hence, 
we wanted to investigate whether these proteins had a role to play in mediating lapatinib 
resistance in WT-AD cells. However, we noted that inhibition of neither Src family kinases 
(using the inhibitor PP2) nor IGF-1 receptor function (using the inhibitor PPP) restored 
lapatinib sensitivity in WT-AD cells (Figure 14). It is noteworthy that inhibition of the 
IGF-1 receptor using PPP caused significant toxicity in WT cells but not in WT-AD cells, 
arguing that WT-AD cells are also cross-resistant to agents that inhibit the function of 
other receptor tyrosine kinases that are known to compensate for ERBB survival signaling. 
As mentioned previously, constitutive activation of a variety of transcription factors such 
as nuclear factor κB (NFκB) and signal transducers and activators of transcription (STAT) 
have been implicated in mediating drug resistance (Herrmann JL, et. al. 1997; Sumitomo 
M, et. al. 1999; Bewry NN, et. al. 2008). In order to investigate whether NFκB was 
invovled in mediating lapatinib resistance, WT and WT-AD cells were infected with 
adenovirus that over-expressed IκB super-repressor. NFκB is usually sequestered in the 
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cytosol by inhibitor of κB (IκB) (Baldwin AS. 2001). IκB kinase (IKK) phosphorylates 
IκB which leads to its degradation, releasing NFκB to perform its functions (Baldwin AS. 
2001). However, the super-repressor IκB (S32A) lacks one of the residues that is required 
to be phosphorylated by IKK to allow IκB to release NFκB. In the presence of super-
repressor IκB (S32A), NFκB activation is constitutively inhibited. Hence, if lapatinib 
resistance in WT-AD cells was due to constitutive NFκB activation, infection of these cells 
with super-repressor IκB would inhibit NFκB activation and therefore render WT-AD cells 
lapatinib sensitive. However, WT-AD cells maintained lapatinib resistance in spite of 
constitutive NFκB inhibition (Figure 15B). This indicated that NFκB was not likely 
invovled in mediating lapatinib resistance in WT-AD cells. To investigate the invovlement 
of STAT proteins, STAT inhibitory peptide was introduced in WT-AD cells. STAT 
inhibitory peptide is known to significantly lower the DNA-binding activity of STAT 
proteins by forming an inactive STAT:peptide complex and reduce the levels of active 
STAT:STAT dimers that can bind to promoter elements and induce transcription of genes 
involved in migration, survival and proliferation (EMD Biosciences). It was noted that 
treatment of WT-AD cells with STAT inhibitory peptide did not make them sensitive to 
the effects of lapatinib suggesting that STAT proteins were not primary candidates 
involved in mediating lapatinib resistance in WT-AD cells (Figure 15C).  
Previous studies have shown that the estrogen receptor can mediate lapatinib resistance in 
BT474 breast cancer cells (Xia W, et. al. 2006). Some colon cancer cells have been known 
to express estrogen receptor (Cho NL, et. al. 2007; Xia W, et. al. 2006). Tamoxifen is a 
selective estrogen receptor modulator (SERM) and is thought to antagonize the estrogen 
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receptor in most tissues (Riggs BL and Hartmann LC. 2003). Hence, to investigate whether 
estrogen receptor was involved in mediating lapatinib resistance in WT-AD cells, these 
cells were treated with 4-hydroxy tamoxifen (one of the active metabolites of tamoxifen) in 
phenol-red free media since phenol-red is a weak estrogen mimic and its presence may 
alter the effect of 4-hydroxy tamoxifen in WT-AD cells (Reddel RR, et. al. 1983; Berthois 
Y, et. al. 1986). Results showed that inhibition of estrogen receptor did not revert lapatinib 
resistance in WT-AD cells indicating that unlike in BT474 breast cancer cells, estrogen 
receptor did not appear to be invovled in mediating lapatinib resistance in WT-AD cells 
(Figure 15A) (Xia W, et. al. 2006). In control studies, we noted that expression of super-
repressor IκB, treatment with STAT inhibitory peptide or 4-hydroxy tamoxifen suppressed 
reporter construct activity in parental and lapatinib resistant cells confirming that these 
agents were functional (Figure 16).  
Multi drug resistance pumps (MDR pumps) have been implicated in mediating drug 
resistance in a variety of cancer cells as they can pump toxic drugs out of cells (Szakacs G, 
et. al. 2006). In WT-AD cells, drug efflux could be a mechanism of lapatinib resistance, 
particularly as we observed cross-resistance to multiple cytotoxic therapeutic drugs. Hence, 
we performed immunoblotting analyses to determine the expression of multidrug-resistant 
plasma membrane drug transporters that have been commonly implicated in mediating 
drug resistance in cancer cells. Comparing WT and WT-AD cells, no obvious change in 
the protein level of membrane drug transporters tested was observed arguing that changes 
in drug efflux was unlikely to be a major component of the lapatinib-resistance mechanism 
in WT-AD cells (Figure 17). 
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Since we were unable to identify candidates responsible for mediating lapatinib resistance 
in WT-AD cells, we decided to look at other molecules known to modulate cell death 
pathways. Immunoblotting analyses showed that compared to WT cells, WT-AD cells 
expressed higher levels of Mcl-1, Bcl-xl, p53 proteins and lower levels of pro-apopotic 
protein BAX (Figure 18). Unlike WT-AD cells, lapatinib treatment in WT cells induced 
BAK and BAX activation (Figure 18). It was noted that total BAK levels increased in 
lapatinib treated WT-AD cells but no obvious increase in BAK activation was noticed 
under the same conditions (Figure 18). This may occur because the increased levels of pro-
apoptotic proteins Bcl-xl and Mcl-1 may be able to sequester any up-regulated BAK and 
prevent it from being activated thereby inhibiting activation of cell death pathways. Hence, 
these alterations in the Bcl-2 family proteins in WT-AD cells are likely to profoundly 
protect these cells from toxic insults. Along the same lines, it was also noted that over-
expression of anti-apoptotic protein Bcl-xl protected WT cells from the toxic effects of 
lapatinib (Figure 19). Based on the established concept of the so-called “apoptotic 
rheostat,” in which the anti-apoptotic Bcl-2 family proteins act in a dynamic balance to 
suppress the pro-apoptotic signals generated by proteins such as BAX and BAK, our data 
suggest that WT-AD cells could be resistant to lapatinib compared to WT cells because 
they have increased expression of the mitochondrial protective proteins Bcl-xl and Mcl-1, 
reduced expression of the mitochondrial toxic protein BAX and reduced activation of pro-
apoptotic proteins BAK and BAX upon lapatinib treatment.   
Since WT-AD cells had increased expression of anti-apoptotic Bcl-xl and Mcl-1 proteins, 
we wanted to investigate whether knock-down of expression of one or both of these 
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proteins would render WT-AD cells sensitive to lapatinib. Results showed that knock-
down of Mcl-1 expression partially reverted lapatinib resistance in WT-AD cells to a 
greater extent than by knock-down of Bcl-xl expression (Figure 20). Recent studies have 
shown that over-expression of Mcl-1, but not Bcl-2 or Bcl-xl, abrogated BAK activation 
after exposure to ABT-737 (a Bcl-2/Bcl-xl inhibitor) and roscovitine (a cyclin-dependent 
kinase inhibitor), arguing that Mcl-1 plays a major role in regulating BAK function (Chen 
S, et. al. 2007). This is consistent with data demonstrating that Mcl-1 binds with greater 
affinity to BAK compared with Bcl-xl (IC50 < 10 versus < 100 nM) (Willis SN, et al. 
2005). In WT-AD cells, knock-down of BAK activation significantly reduced the reversion 
of their resistant phenotype by reduced Mcl-1 expression (Figure 21). Thus, the 
mechanism of lapatinib resistance in WT-AD cells seems to be in part due to the loss of 
BAX expression and loss of BAK activation primarily due to over-expression of Mcl-1. 
Along these lines, a recently published study showed that in human H3255 non-small-cell 
lung cancer cells, Erlotinib (a tyrosine kinase inhibitor of ERBB1) induced mitochondria-
mediated apoptosis via loss of mitochondrial membrane potential, cytosolic cytochrome c 
release and activation of BAK and BAX proteins (Ling YH, et. al. 2008). 
The tumor suppressor protein p53, known as the “guardian of the genome”, can regulate 
the cell cycle and prevent its progression upon recognition of DNA damage or other 
cellular insults (Read AP and Stachan T. 1999; Bhana S and Llyod DR. 2008). p53 can 
also activate DNA damage repair proteins and can activate cell death cascades if the DNA 
damage appears to be irreparable (Offer H, et. al. 2002). It is known that WT cells express 
wild-type p53 (Zawacka-Pankau J, et al. 2007). In our studies to determine the mechanism 
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of lapatinib resistance, we noted that p53 was over-expressed in WT-AD cells and that the 
expression of a transcriptional target of p53, BAX, was lower in these cells compared to 
WT cells (Figure 18). It is known that in cancer cells, expression of p53 is often elevated 
when it is mutated (Kohler MF, et al. 1992). It was also noted that p53 phosphorylation 
was reduced in WT-AD cells compared to WT cells under vehicle as well as lapatinib 
treated conditions (Figure 18). This is important since phosphorylation of p53 has been 
shown to play an important role in stabilizing and activating p53 so that it can elicit an 
appropriate response to cellular stress (Jimenez GS, et. al. 1999). Hence the lack of p53 
phosphorylation may suggest that WT-AD cells may be able to avoid activation of cell 
death pathways due to lack of appropriate activation of p53. Together, these data suggested 
that it was possible that HCT 116 cells expressing a wild-type p53 protein may have 
become lapatinib resistant by developing a p53 mutation or by selection of cells already 
bearing a p53 mutation. In agreement with this hypothesis, WT-AD cells but not WT cells 
expressed a p53 protein that could be immunoprecipitated by an antibody that specifically 
recognizes p53 protein mutated in its DNA binding domain (Figure 22). This antibody 
differentiates between wild-type and mutant p53 under non-denaturing conditions since a 
mutation in the DNA binding domain of p53 can alter its tertiary structure such that it 
allows exposure of an epitope that can be recognized by this antibody (Gannon JV, et. al. 
1990). This epitope is usually hidden and therefore not exposed to the antibody in the 
correctly folded structure of wild-type p53 protein. To further identify whether there 
existed a mutation in p53 in WT-AD cells, gene sequencing was performed. However, 
upon sequencing the coding regions in the DNA binding domains of p53, no mutations 
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were noted in WT-AD cells. This suggests that our antibody was recognizing an alteration 
in p53 tertiary conformation in WT-AD cells unrelated to a p53 DNA binding domain 
mutation but that was in all likelihood still suppressing p53 function (i.e., reduced BAX 
expression) or that p53 mutation had occurred in a domain unrelated to the DNA binding 
domain of p53 but that was affecting the tertiary conformation of the DNA binding 
domain.  
Further studies are required to understand how p53 function, with respect to modulation of 
all p53 targets has been altered in lapatinib resistant HCT116 cells. 
Next, we wanted to determine whether lapatinib mediated toxicity in WT cells depended 
solely on inhibition of ERBB1 and ERBB2 receptors and their downstream pro-survival 
pathways. Since lapatinib is thought to mediate its effects by inhibition of ERBB1 and 
ERBB2 function, we wanted to mimic this effect using adenovirus-mediated expression of 
dominant negative ERBB1 (CD533) and dominant negative ERBB2 (CD572) proteins 
(Wood ER, et. al. 2004; Rusnak DW, et. al. 2001). CD533 and CD572 function as 
dominant negative ERBB1 and ERBB2 receptors, respectively because they have truncated 
C-terminal kinase domains, therefore forming non-functional dimers with wild-type 
receptors (Imai K and Takaoka A. 2006; Schmidt-Ullrich RK, et. al. 2003). In spite of 
being able to inhibit ERBB1 and ERBB2 receptor phosphorylation similar to lapatinib in 
WT cells, the dominant-negative receptors did not recapitulate the toxic effects of lapatinib 
in serum-starved WT or WT-AD cells (Figure 23). This suggests that there are possibly 
other targets that lapatinib inhibits/interacts with that may play an important role in 
inducing toxic effects mediated by lapatinib.  
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Since we observed changes in the expression of proteins that act at the mitochondrion to 
modulate mitochondrial stability, we next determined whether activation of caspase 
proteases played a role in lapatinib toxicity. Caspases are known to activate cell death 
pathways by activating pro-apoptotic Bcl-2 family members that can then alter 
mitochondrial integrity or vice versa (Gross A, et. al. 1999). Serum-starvation has been 
known to induce cell death by activation of caspases (Kilic M, et. al. 2002). Inhibition of 
caspase 8 and caspase 9 using IETD and LEHD (inhibitors for the respective enzymes), as 
well as using zVAD (a pan-caspase inhibitor), significantly reduced the level of cell death 
induced by serum-starvation in WT cells (Figure 24). However, inhibition of caspase 8, 
caspase 9 or pan-inhibition of caspase function did not suppress lapatinib toxicity in 
serum-starved WT cells (Figure 25). This suggested that lapatinib mediated cell death 
involves caspase-independent mechanisms. Since other enzymes such as calpains, 
cathepsins and serine proteases have also been implicated in activating cell death 
pathways, we wanted to determine whether these factors were involved in lapatinib 
mediated cell death (Vandenabeele P, et. al. 2005; Droga-Mazovec G, et. al. 2008; Broker 
LE, et. al. 2004). However, inhibiting these enzymes did not significantly protect WT cells 
from lapatinib induced cell death, indicating that these enzymes are not prime mediators of 
lapatinib toxicity in WT cells (Figure 26, 27).  
To investigate caspase-independent mechanisms of lapatinib mediated cell death, we 
decided to focus on apoptosis inducing factor (AIF). AIF is normally present in the inter-
membrane space of the mitochondrion, tethered to the inner mitochondrial membrane 
(Otera H, et. al. 2005). In certain stressful situations, AIF is cleaved, released into the 
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cytosol upon mitochondrial outer membrane permeablization (MOMP) and it then makes 
its way to the nucleus where it can initiate DNA fragmentation (Modjtahedi N, et. al. 2006; 
Penninger JM and Kroemer G. 2003). Cell fractionation studies showed that AIF was 
released into the cytosol of WT cells treated with lapatinib but a similar increase in 
cytosolic release of AIF was not observed in WT-AD cells under the same treatment 
conditions (Figure 28). Similar results were observed for cytochrome c although 
cytochrome c is typically thought to be involved in caspase-dependent cell death pathways 
(Figure 28). However, it has been suggested that cytochrome c release can occur in caspase 
independent cell death due to MOMP and this can occur after AIF release because 
electrostatic interactions with cardiolipin can retain cytochrome c at the inner 
mitochondrial membrane and hence, delay its release (Uren RT, et. al. 2005). Knock-down 
of AIF expression in WT cells protected them from lapatinib mediated toxicity and knock-
down of AIF expression combined with pan-caspase inhibition further reduced cell death 
induced by lapatinib in these cells (Figure 29). These results suggested that AIF is a key 
player in lapatinib mediated cell death in WT cells and failure of AIF cytosolic release in 
lapatinib treated WT-AD cells possibly protected them from cell death.  
Our results show that an alteration in the Bcl-2 family proteins has an important role to 
play in mediating lapatinib resistance in HCT 116 cells. Future studies involving Bcl-
2/Bcl-xl/Mcl-1 antagonists such as obatoclax, combined with lapatinib will need to be 
performed in order to determine whether such drugs will enhance the lethality of lapatinib 
as well reduce the chances of occurrence of lapatinib resistant cancers. Also, our studies 
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suggest that the mechanism of lapatinib mediated toxicity in WT cells may involve effects 
of lapatinib on targets other than ERBB1 and ERBB2. 
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OBATOCLAX ENHANCES SORAFENIB+HDACI TOXICITY AND 
OVERCOMES BLOCKADE OF CD95 PATHWAY TO FACILITATE KILLING 
 
 
A. Introduction: 
The Raf-MEK1/2-ERK1/2 pathway is frequently dysregulated in neoplastic transformation 
(Dent P, et. al. 2003; Valerie K, et. al. 2007). The MEK1/2-ERK1/2 module comprises, 
along with c-Jun NH2-terminal kinase (JNK1/2) and p38 MAPK, members of the MAPK 
super-family. These kinases are involved in responses to diverse mitogens and 
environmental stresses and have also been implicated in cell survival processes. Activation 
of the ERK1/2 pathway is often associated with promoting cell survival whereas JNK1/2 
and p38 MAPK pathway signaling often induces apoptosis. Although the mechanisms by 
which ERK1/2 activation promote survival are not fully characterized, a number of anti-
apoptotic effector proteins have been identified, including increased expression of anti-
apoptotic proteins such as c-FLIP, Bcl-xl and Mcl-1 and also direct inactivation of pro-
apoptotic proteins such as caspase 9, BAD and BIM (Grant S and Dent P. 2004; Allan LA, 
et. al. 2003; Mori M, et. al. 2003; Ley R, et. al. 2003; Wang WF, et. al. 2007; Qiao L, et. 
al. 2003). In view of the importance of the RAF-MEK1/2-ERK1/2 pathway in neoplastic 
cell survival, inhibitors have been developed that have entered clinical trials, such as 
sorafenib (4-[4-[[4-chloro-3-(trifluoromethyl)phenyl] carbamoylamino] phenoxy]-N-
methyl-pyridine-2-carboxamide, Bay 43-9006, Nexavar®; a Raf kinase inhibitor) (Li N, et. 
al. 2007). Sorafenib is a multi-kinase inhibitor that was originally developed as an inhibitor 
of Raf-1 (c-Raf). Sorafenib occupies the ATP-binding domain of Raf-1 and B-Raf, there 
by preventing ATP from binding the kinase (Wan P, et. al. 2004). Subsequently however, 
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sorafenib was shown to inhibit multiple other kinases, including platelet-derived growth 
factor, vascular endothelial growth factor receptors 1 and 2, c-Kit and FLT3 (14). 
Sorafenib is also known to inhibit mutant V559EB-Raf (Wilhelm S and Chien DS. 2002). It 
is important to note that sorafenib did not significantly increase cell death in non-
transformed cells (Rosato RR, et. al. 2007). Anti-tumor effects of sorafenib in renal cell 
carcinoma and in hepatoma have been ascribed to anti-angiogenic actions of this agent 
through inhibition of the growth factor receptors (Rini BI. 2006; Gollob JA. 2005). 
Sorafenib has also been shown to inhibit tumor cell proliferation and tumor xenograft 
growth (Wilhelm SM, et. al. 2004). Previous studies have shown in vitro that sorafenib 
kills human leukemia cells at concentrations below the maximum achievable dose (Cmax) 
of 15-20 µM, through a mechanism involving down-regulation of the anti-apoptotic Bcl-2 
family member Mcl-1 (Rahmani M, et. al. 2005; Rahmani M, et. al. 2007a). In these 
studies sorafenib-mediated Mcl-1 down-regulation occurred through a translational rather 
than a transcriptional or post-translational process that was mediated by endoplasmic 
reticulum stress signaling (Dasmahapatra G, et. al. 2007; Rahmani M, et. al. 2007b). 
Hence, previously observed anti-tumor effects of sorafenib are mediated by a combination 
of inhibition of Raf family kinases; receptor tyrosine kinases that signal angiogenesis; and 
the induction of ER stress signaling.  
There are 18 known histone deacetylases (HDACs) in humans and these can be divided 
into three classes: Class I include HDAC1, HDAC2, HDAC3 and HDAC8; Class II 
include HDAC4, HDAC5, HDAC7 and HDAC9. HDAC6 and HDAC10 belong to Class 
IIa and have two catalytic sites. HDAC11 shares characteristics with both Class I and Class 
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II and hence is often placed in Class IV. Class III HDACs include sirtuins that require 
NAD+ for their activity, lack zinc in their catalytic sites and are not inhibited by commonly 
used HDACIs such as vorinostat (suberoylanilide hydroxamic acid, SAHA, ZolinzaTM) 
(Dokmanovic M, et. al. 2007; Marks P, et. al. 2001). HDACs, along with histone acetyl-
transferases (HATs), reciprocally regulate the acetylation status of the positively charged 
NH2-terminal histone tails of nucleosomes there by regulating transcription of genes 
(Gregory PD, et. al. 2001). HDACs can act not only on histones but on other proteins as 
well such as p53. Acetylation of p53 can lead to increased sequence specific binding 
activity and hence increased transcription of p53 target genes (Tang Y, et. al. 2008). 
HDACs can deacetylate p53 which can decrease the ability of p53 to transcribe target 
genes (Glozak MA, et. al. 2005). Alterations in HATs and HDACs have been found in a 
variety of cancers. Alterations in expression levels of HDACs have been observed in 
certain cancers; however, structural mutations in HDACs are a rare event in cancer cells 
(Bolden JE, et. al. 2006; Marks P, et. al. 2001; Dokmanovic M, et. al. 2007). Aberrant 
activity of HDACs in cancer cells is often associated with HDACs being recruited by 
oncogenic translocation protein complexes (Wilson AJ, et. al. 2006). Histone deacetylase 
inhibitors (HDACI) represent a class of agents that act by blocking histone de-acetylation, 
thereby modifying chromatin structure and gene transcription. HDAC inhibitors (HDACIs) 
promote histone acetylation and neutralization of positively charged lysine residues on 
histone tails, allowing chromatin to assume a more open conformation, which favors 
transcription (Gregory PD, et. al. 2001). Most HDACIs are thought to function by binding 
to the zinc atom in the HDAC catalytic site thereby inhibiting the enzyme’s activity 
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(Richon VM. 2006; Taddei A, et. al. 2005). However, HDACIs have also been known to 
have plieotropic biological consequences, including inhibition of chaperone HSP90 
function (thought to be required for survival of oncogenic fusion proteins), induction of 
oxidative injury and up-regulation of death receptor expression (Dasmahapatra G, et. al. 
2007; Marks PA, et. al. 2003; Bali P, et. al. 2005; Kwon SH, et. al. 2002).  
Vorinostat is a hydroxamic acid HDACI that has shown preliminary pre-clinical evidence 
of activity in hepatoma and other malignancies with a Cmax of ~9 µM (Wise LD, et. al. 
2007; Zhang G, et. al. 2008). Vorinostat is a pan-inhibitor of HDACs belonging to classes 
I and II and has been known to induce growth arrest in a variety of transformed cells 
(Marks PA and Breslow R. 2007; Mitsiades CS, et. al. 2004). Vorinostat was also found to 
be efficacious in vivo by inhibiting the growth of human cancer xenografts (Marks PA, et. 
al. 2005). Vorinostat is known to increase reactive oxygen species (ROS) in cancer cells 
but not in normal cells. In addition, vorinostat can increase the levels of thioredoxin 
binding protein-2 in cancer cells thereby reducing thioredoxin (known to have ROS 
scavenging function) levels and this may facilitate ROS mediated cell death in cancer cells 
(Marks PA and Breslow R. 2007). This can explain, at least in part, the relative resistance 
to vorinostat toxicity in normal cells and the sensitivity of many cancer cells.  
Valproic acid is used as an anti-epileptic drug and also as a mood-stabilizer (Robert E, 
1991). It has been known to have teratogenic effects that have now been linked to its 
ability to inhibit HDAC activity which is also thought to be responsible for its ability to 
inhibit tumor growth, proliferation, angiogenesis, induction of differentiation and 
radiosensitization in certain cancer cells (Alsdorf R and Wyszynski DF. 2005; Cinatl J. Jr., 
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et. al. 1997; Duenaz-Gonzalez A, et. al. 2008). Valproic acid administered alone or in 
combination with other agents such as cytosine arabinoside, hydroxyurea, cisplatin and 
etoposide has been shown to be effective in killing cancer cells (Blaheta RA, et. al. 2005; 
Gupta E, et. al. 1997). Valproic acid is a much weaker inhibitor of HDAC activity than 
vorinostat and is known to inhibit the function of Class I (1, 2, 3)and Class II (4, 5, 7) 
HDACs (Xu W, et. al. 2007; Gurvich N, et. al. 2004).  
With respect to combinatorial drug studies with a multi-kinase inhibitor such as sorafenib, 
HDACIs are of interest in that they have potential to down-regulate multiple oncogenic 
kinases by interfering with HSP90 function, leading to proteasomal degradation of these 
proteins. Sorafenib and HDACIs target multiple overlapping downstream signaling 
pathways implicated in tumor cell survival. Hence, if combined, there was a possibility 
that the two drugs administered together would be more effective than either drug 
individually and also that lower doses of these agents may be required to observe toxic 
effects on cancer cells. Previous studies have shown that low doses of sorafenib and 
vorinostat can act synergistically in a variety of cancer cells (Zhang G, et. al. 2008; Park 
MA, et. al. 2008). This drug combination is known to activate the de novo ceramide 
synthesis pathway which along with the acidic sphingomyelinase ceramide generation 
pathway initiates CD95 death receptor activation. Hence, according to previous studies,  
sorafenib and vorinostat mediated cell death is thought to occur via ligand independent but 
ceramide dependent activation of the CD95 death receptor signaling pathway and this drug 
combination is now entering Phase I clinical trials (Zhang G, et. al. 2008; Park MA, et. al. 
2008). It is important to note that previous studies have shown that unlike cancer cells, 
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sorafenib and vorinostat combined failed to cause significant cell death in normal bone 
marrow cells (Dasmahapatra G, et. al. 2007). Studies have shown that sorafenib interacts 
with other HDACI (such as Trichostatin A and sodium butyrate) as well to markedly 
increase lethality in cancer cells (Dasmahapatra G, et. al. 2007).  
This study investigated whether low dose of sorafenib combined with sodium valproate 
(another HDACI, sodium salt of valproic acid) also acted synergistically to kill cancer cells 
and whether CD95 death receptor activation had a role to play in mediating cell death 
under these conditions. 
Several cancers are known to lose CD95 expression/function and this can enable cells to 
become resistant to chemotherapeutic agents that utilize the CD95 signaling pathway to 
mediate cell death (Ozoren N and El-Deiry WS. 2003; Los M, et. al. 1997; Houston A and 
O’Connell J. 2004). Increased expression of mitochondrial protective proteins such as Mcl-
1 and Bcl-xl have also been implicated in mediating drug resistance in cancer cells (Martin 
AP, et. al. 2008; Del Poeta G, et. al. 2008). Since previous studies show that sorafenib and 
HDACI combine synergistically to cause cell death via CD95 signaling, it was possible 
that in the clinic, resistance to these agents may occur via dysregulation of the CD95 
signaling pathway. Hence, it would be logical to combine sorafenib and HDACIs with an 
agent that facilitated cell death independent of CD95 by targeting the mitochondrial 
protective proteins and could synergize with the two drugs to result in enhanced cell death. 
Theoretically, this would reduce the likelihood of tumor cells being inherently resistant as 
well as potentially circumventing the development of drug resistant cancers.      
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Obatoclax (GX 15-070) is a small molecule antagonist of the BH-3 binding domain of the 
Bcl-2 family proteins and is known to mediate its effects in cancer cells independent of the 
CD95 pathway via inhibition of Mcl-1-BAK interaction, BIM upregulation and 
cytochrome c release into the cytosol (Trudel S, et. al. 2007). Short term toxicity assays 
showed that obatoclax has minimal effects on normal human peripheral blood lymphocyte 
viability where as significant reduction in cell viability was observed in obatoclax treated 
cancer cells (Trudel S, et. al. 2007). Hence, we investigated whether obatoclax enhanced 
the toxicity of sorafenib and sodium valproate and whether this three-drug combination 
maintained high cell death levels in spite of knock-down of CD95 in cancer cells.  
B. Materials: 
Sorafenib tosylate was generously provided by Bayer Inc. Vorinostat was generously 
provided by Merck & Co., Inc. GX15-070 was generously provided by Gemin X 
Pharmaceuticals. Trypsin-EDTA, DMEM, RPMI, penicillin-streptomycin were purchased 
from GIBCOBRL (GIBCOBRL Life Technologies, Grand Island, NY). Sodium valproate 
was purchased from Sigma. Fetal bovine serum was purchased from hyclone (Logan, UT). 
Trypan blue dye and crystal violet were purchased from Sigma-Aldrich. For western blot 
analysis, 8-16% gels were used (BIORAD, Carlsbad, CA). HEPG2, HEP3B and PANC1 
cells were purchased from the ATCC. Commercially available validated short hairpin 
RNA molecules to knock down RNA/protein levels were purchased from Qiagen 
(Valencia, CA). Primary antibodies recognizing BAX, BAK, BIM, Mcl-1 and cytochrome 
c were purchased from Cell Signaling (San Diego, CA). Primary antibody for active BAK 
(Ab-1) was purchased from Calbiochem (San Diego, CA). Primary antibodies for GAPDH, 
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active BAX (6A7) and protein A/G plus agarose beads for immunoprecipitation were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary mouse antibody 
was purchased from Invitrogen Molecular Probes (Eugene, OR) and secondary rabbit 
antibody was purchased from Rockland (Gilbertsville, PA). All siRNAs were pruchased 
from Qiagen. C-FLIP-s virus was purchased from Vector Biolabs. DAPI stain was 
purchased from Vector Laboratories Inc (Burlingame, CA).              
 
Methods: 
Cell Culture: Panc1 pancreatic cancer cells were cultured in DMEM media containing 
DMEM media containing 20% fetal bovine serum and 1% Penicillin/Streptomycin. 
HEPG2 and HEP3B hepatic cancer cells were culture in MEM Alpha media containing 
10% fetal bovine serum and 1% Penicillin/Streptomycin supplemented with sodium 
pyruvate, sodium bicarbonate and non-essential amino acids.  
Detection of Cell Death by Trypan Blue Assay: After treatment, medium was removed 
and cells were washed in 1X PBS. Cells were then harvested by trypsinization with 
Trypsin/EDTA for 5 min at 37°C. Because some apoptotic cells detached from the culture 
substratum into the medium, these cells were also collected by centrifugation of the 
medium at 1400 RPM for 5 min. The pooled cell pellets were resuspended and mixed with 
trypan blue dye. Trypan blue stain, in which blue dye-incorporating cells were scored as 
being dead, was performed by counting of cells using a light microscope and a 
hemacytometer. The number of dead cells was counted and expressed as a percentage of 
the total number of cells counted. 
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Culture of Cells and Drug Treatments for Colony Formation Assays: Cells were 
plated (250–1000 cells/well of a 6-well plate). 12 h after plating medium was removed and 
serum-free medium was added to the cells for 24 or 48 h as indicated. After this, the serum-
free media was carefully removed and fresh media (with serum) was added. Colony 
formation assays were cultured for an additional 8-10 days, after which the media were 
removed, cells were fixed with methanol, stained with crystal violet, and counted manually. 
Immunoprecipitation and Western Blotting: 12 hours after plating cells, they were 
treated with various drugs as indicated. 12, 24 or 48 h after drug treatment, cells were lysed 
in whole cell lysis buffer (0.5 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% β-
mercaptoethanol, 0.02% bromophenol blue).  
12 hours after plating cells, they were treated with drugs as indicated and 24 h after drug 
treatment, cells were scraped in CHAPS buffer (10mM HEPES, 140mM NaCl, 1% 
CHAPS) and then active BAK, active BAX or Mcl-1 was immunoprecipitated. Samples 
were boiled for 10 min in whole cell lysis buffer. All samples were then loaded on 8%-
16% Criterion pre-cast gels (BIORAD) after normalizing total protein and run for about 2 
hours. Proteins were then electrophoretically transferred onto 0.22um nitrocellulose 
membranes and immunoblotted with various primary antibodies as indicated.  
Virus Infections: Cells were infected 12h after plating with adenoviruses at an 
approximate multiplicity of infection of 30 for 4 h with gentle rocking, after which time the 
media was replaced. Cells were further incubated for 24 h to ensure adequate expression of 
transduced gene products before drug exposures. 
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Transfection of Cells with Small Interfering RNA Molecules: RNA interference for 
down-regulating the expression of various molecules was performed using validated target 
sequences designed by Qiagen. For transfection, 20-40 nM concentration of the annealed 
siRNA-targeting Mcl-1, Bcl-xl or Bcl-2, or the negative control (a "scrambled" sequence 
with no significant homology to any known gene sequences from mouse, rat, or human cell 
lines) were used. The siRNA molecules were transfected into cells according to the 
manufacturer's instructions. Cells were cultured for 24 h after transfection before any 
additional experimentation. 
Cell Fractionation: 12h after plating cells, they were treated with drugs as indicated. 12 or 
24 h later, medium from plates was aspirated and cells were scraped in buffer (75mM 
NaCl+8mMNa2HPO4+1mMNa2H2PO4+0.5mMEDTA+ 0.5mMEGTA with freshly added 
350ug/ml digitonin, 250mM sucrose, protease and phosphatase inhibitor cocktails (Roche)) 
and passed through a 25 gauge needle 10 times. After 15 to 30 minutes on ice, cells were 
spun down at 5000RPM for 1.5 minutes at 4oC to remove cell debris. Pellet was discarded 
and supernatant was transferred to a new tube and spun down at 13000 RPM for 25 
minutes at 4oC. The supernatant obtained is the cytosolic fraction where as the pellet is the 
mitochondrial fraction. Whole cell lysis buffer was added to the supernatant and the pellet, 
boiled for 10 minutes and then western blot analysis was performed. This protocol was 
adapted from Leist M, et. al. (1998). 
CD95 cell surface localization: Cells were washed once in DPBS and fixed with 4% 
paraformaldehyde in DPBS. Slides were washed again in DPBS and placed in a humidified 
chamber. Blocking solution (1% bovine serum albumin and 2% rat serum in DPBS) was 
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added to the cells for 1 hour at room temperature. 1:100 diluted CD95 antibody was then 
added to the cells that were then placed in a humidified chamber at 4 degrees Celsius 
overnight. The next day, cells were washed once in DPBS and secondary antibody (R-488) 
was added diluted 1:300 for an hour. Cells were then washed in DPBS and vectashield 
with Dapi stain was added to the cells which were then cover-slipped and read at 100X 
magnification.  
DAPI staining: Cells were washed once with DPBS and fixed for 20 minutes with 4% 
paraformaldehyde (in PBS). Chamber covers were removed from the slides and cells were 
washed in DPBS once. Mounting media containing DAPI staining was added to cells and 
slides were coverslipped.  
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D. Results: 
Effect of sorafenib + vorinostat on cell survival and death: Colony formation assays 
show that sorafenib and vorinostat act synergistically in Panc1 cells to reduced cell 
survival (Table 1). Trypan blue analysis also showed that sorafenib and vorinostat 
combination can induce significantly higher levels of cell death compared to vehicle or 
individual drug treatments in Panc1 cells (Figure 30), HEP3B cells (Figure 31) and also in 
HEPG2 cells (Figure 32).  
CD95 pathway in sorafenib + vorinostat induced death: We wanted to confirm previous 
studies that showed that sorafenib and vorinostat mediated toxicity occured via CD95 
activation (Zhang G, et. al. 2008; Park MA, et. al. 2008). Knock-down of CD95 using 
siRNA protected Panc1 cells from sorafenib and vorinostat induced cell death as 
determined by trypan blue assay (Figure 33). 
c-FLIP-s is a negative regulator of the CD95 pathway and hence, we wanted to investigate 
whether over-expression of c-FLIP-s would protect cells from sorafenib and vorinostat 
mediated toxicity (Krueger A, et. al. 2001). Results showed that over-expression of c-
FLIP-s protected Panc1 cells from sorafenib and vorinostat induced cell death as 
determined by trypan blue assay (Figure 34). DAPI staining also showed that over-
expression of c-FLIP-s protected cells from sorafenib and vorinostat induced DNA 
fragmentation (Figure 35).  
Effect of sorafenib + sodium valproate on cell survival and death: We wanted to 
determine whether sorafenib combined with sodium valproate (also a HDACI) would also 
act synergistically to kill cancer cells. For all short term cell viability experiments, we used 
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1mM dose of sodium valproate which is a clinically relevant dose (Ueshima S, et. al. 
2008). Colony formation assays showed that sorafenib and sodium valproate act 
synergistically in Panc1 and HEP3B cells to reduced cell survival (Table 1, 2). Trypan blue 
analysis also showed that sorafenib and sodium valproate in combination can induce 
significantly higher levels of cell death compared to vehicle or individual drug treatments 
in Panc1 and HEPG2 cells (Figure 36, 37).  
Mitochondrial translocation of BAX upon sorafenib+sodium valproate treatment: We 
next investigated the proteins that may be involved in mediating sorafenib and sodium 
valproate toxicity. Cell fractionation studies showed that 12 h after treatment with 
sorafenib and sodium valproate combined in HEPG2 cells, BAX translocation from 
cytosol to mitochondrial was observed (Figure 38).  
BIM and BAK co-immunoprecipitation with MCL-1 in sorafenib + sodium valproate 
treated cells: In HEPG2 cells, immunoblotting studies failed to show any significant 
change in Mcl-1 expression level 6 h post sorafenib and sodium valproate treatment 
(Figure 39). However, at this time-point, immunoprecipitation studies showed that BAK 
association with Mcl-1 was decreased in cells treated with the drug combination compared 
to vehicle treated cells (Figure 39). 12 h after drug combination treatment, total Mcl-1 
expression level as well as levels of BIM and BAK associated with Mcl-1 appeared to be 
significantly reduced compared to vehicle treated cells (Figure 39).  
CD95 cell surface localization in sorafenib + sodium valproate treated cells: 6 h after 
treating HEPG2 cells with vehicle, 3μM sorafenib alone, 1mM sodium valproate alone or 
the two drugs together, CD95 cell surface localization was determined (Figure 40). This 
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time point was chosen since previous studies have shown that sorafenib and vorinostat 
combined result in CD95 cell surface localization/activation as early as 6 h post drug 
treatment (Zhang G, et. al. 2008). We observed that 6h after drug treatment, CD95 
localization at the cell surface was much greater in HEPG2 cells treated with 
sorafenib+sodium valproate compared to other conditions. 
Effect of obatoclax in combination with sorafenib alone: We wanted to investigate 
whether inhibition of Bcl-2 family members via obatoclax would enhance cancer cell 
killing when combined with sorafenib alone. Obatoclax treatment resulted in significantly 
higher cell death compared to vehicle treated HEPG2 cells (Figure 41). Obatoclax and 
sorafenib combined resulted in significantly higher cell death compared to sorafenib alone 
at 3μM and 6μM doses of sorafenib (Figure 41). At all other doses of sorafenib tested, the 
presence of obatoclax did not significantly enhance cell death compared to vehicle treated 
cells (Figure 41). 
Effect of obatoclax in combination with vorinostat alone: We wanted to investigate 
whether inhibition of Bcl-2 family members via obatoclax would enhance cancer cell 
killing when combined with vorinostat alone. Results showed that obatoclax alone induced 
significantly higher cell death in HEPG2 cells compared to vehicle treated cells (Figure 
42). Increasing concentrations of vorinostat, alone or in combination with obatoclax, failed 
to have a significant effect on cell death compared to respective vehicle treated conditions 
(Figure 42). 
Effect of obatoclax in combination with sodium valproate alone: We wanted to 
investigate whether inhibition of Bcl-2 family members via obatoclax would enhance 
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cancer cell killing when combined with sodium valproate alone. In HEPG2 cells, obatoclax 
showed significantly higher levels of cell death compared to vehicle treated cells (Figure 
43). Increasing concentrations of sodium valproate, alone or in combination with 
obatoclax, failed to have a significant effect on cell death compared to respective vehicle 
treated conditions (Figure 43).  
Effect of obatoclax on sorafenib + sodium valproate mediated cell death: We wanted to 
investigate whether inhibition of Bcl-2 family members via obatoclax would enhance 
cancer cell killing when administered to cells treated with sorafenib and sodium valproate 
simulataneuosly. Trypan blue analysis revealed that there were significant effects of 
sorafenib + sodium valproate treatment (at each dose combination tested) and also of 
obatoclax on HEPG2 cell death compared to vehicle treated cells (Figure 44). It was also 
found that the presence of obatoclax significantly enhanced sorafenib + sodium valproate 
induced cell death at each dose combination (Figure 44).  
Effect of CD95 knock-down in sorafenib+sodium valproate+obatoclax treated cells: 
Knock-down of CD95 in HEPG2 cells protected them from the effects of sorafenib and 
sodium valproate alone or in combination and also from obatoclax induced cell death 
(Figure 45). However, CD95 knock-down failed to protect HEPG2 cells from death 
induced by all three drugs (sorafenib+sodium valproate+obatoclax) in combination (Figure 
45).  
Effect of c-FLIP-s over-expression in sorafenib+sodium valproate+obatoclax treated 
cells: c-FLIP-s over-expression in HEPG2 cells protected them from the effects of 
sorafenib and sodium valproate alone or in combination and also from obatoclax induced 
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cell death (Figure 46). However, c-FLIP-s over-expression failed to protect HEPG2 cells 
from death induced by all three drugs (sorafenib+sodium valproate+obatoclax)  in 
combination (Figure 46 ).  
Effect of Bcl-xl, Mcl-1 or Bcl-2 knock-down on sorafenib and sodium valproate induced 
cell death: To investigate whether obatoclax mediated inhibition of any one Bcl-2 family 
member was sufficient to enhance sorafenib+sodium valproate toxicity, HEPG2 cells were 
transfected with siRNA to knock-down Bcl-xl, Mcl-1 or Bcl-2 expression and then treated 
with vehicle or sorafenib and sodium valproate combined. Trypan blue analysis was then 
performed to measure cell viability. Knock-down of Bcl-xl or Bcl-2, but not Mcl-1, 
enhanced sorafenib and sodium valproate induced cell death (Figure 47). 
 
Effect of Bcl-xl and Bcl-2 or Bcl-xl, Mcl-1 and Bcl-2 knock-down on sorafenib and 
sodium valproate induced cell death: HEPG2 cells were transfected with siRNA to knock-
down Bcl-xl and Bcl-2 simultaneously or Bcl-xl, Mcl-1 and Bcl-2 simultaneously and then 
treated with vehicle or sorafenib and sodium valproate combined. Trypan blue analysis 
was performed to measure cell viability. Compared to siSCR treated cells, simultaneous 
knock-down of Bcl-xl and Bcl-2 significantly increased sorafenib and sodium valproate 
induced cell death (Figure 48). Simultaneous knock-down of Bcl-xl, Mcl-1 and Bcl-2 also 
significantly increased sorafenib and sodium valproate induced cell death compared to 
siSCR as well as compared to combined siBcl-xl and siBcl-2 transfected cells (Figure 48). 
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Activation of BAK and BAX: Treatment of HEPG2 cells with sorafenib and sodium 
valproate combined, obatoclax alone or sorafenib + sodium valproate + obatoclax 
combined resulted in increased BAK and BAX activation compared to vehicle treated cells 
suggesting that under these conditions, BAK and BAX are available to initiate cell death 
pathways (Figure 49).  
Cytosolic release of cytochrome c in cells treated with sorafenib, sodium valproate and 
obatoclax: Cell fractionation assays revealed that HEPG2 cells treated with sorafenib + 
sodium valproate + obatoclax showed significant release of cytochrome c into the cytosol 
and correspondingly, a decrease in the mitochondrial levels of cytochrome c was observed 
under the same treatment conditions (Figure 50). These results show that cytosolic 
cytochrome c is available to initiate cell death pathways under this condition. Expression 
of c-FLIP-s appeared to prevent the release of cytochrome c in these cells under basal and 
sorafenib + sodium valproate treatment conditions indicating that blocking the extrinsic 
cell death pathway prevents release of cytochrome c under these conditions (Figure 50). 
However, in spite of c-FLIP-s over-expression, cytosolic release of cytochrome c was 
observed in cells treated with obatoclax alone or sorafenib + sodium valproate + obatoclax 
combined (Figure 50). This confirms that in spite of blocking the CD95 pathway, treating 
cells with sorafenib + sodium valproate + obatoclax combined can result in cytosolic 
cytochrome c release which is then available to activate cell death pathways. 
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Sorafenib        Vorinostat Fa          CI
(uM) (nM)
3.0 250 0.31 0.48
6.0 500 0.42 0.70
9.0 750 0.51 0.83
 
Sorafenib         Valproic Acid Fa CI
(uM) (mM)
3.0 0.50 0.37 0.46
4.5 0.75 0.43 0.58
6.0 1.00 0.54 0.57
7.5 1.25 0.73 0.41
9.0 1.50 0.80 0.37
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Sorafenib synergizes with vorinostat and with sodium valproate in Panc1 
cells. 12h after plating Panc1 pancreatic cancer cells, they were treated with vehicle 
(DMSO), sorafenib and sodium valproate or vorinostat, as indicated at a fixed 
concentration ratio to perform median dose effect analyses for the determination of 
synergy. After drug exposure (48h), the media was changed and cells cultured in drug free 
media for an additional 10-14 days. Cells were fixed, stained with crystal violet and 
colonies of > 50 cells / colony counted. Colony formation data were entered into the 
Calcusyn program and combination index (CI) and fraction affected (Fa) values were 
determined. A CI value of less than 1.00 indicates synergy and larger the Fa value, the 
lower the survival under that condition.  
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Figure 30: Sorafenib and vorinostat combined enhance cell death in Panc1 cells. 12 h 
after plating Panc1 cells, they were treated with Vehicle (DMSO), 3µM sorafenib, 500nM 
vorinostat or 3µM sorafenib and 500nM vorinostat combined. 48 h after drug treatment, 
cell viability was measured using the trypan blue exclusion assay ±S.E.M. n=2. One way 
ANOVA with Bonferroni post-test revealed that sorafenib and vorinostat combined 
induced significantly higher levels of cell death (***, p < 0.0001, n=6) as compared to all 
other treatment conditions. Data (mean ± S.E.M.) are from two independent experiments 
combined. 
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Figure 31: Sorafenib and vorinostat combined enhance cell death in HEP3B cells. 
12 h after plating HEP3B hepatoma cells, they were treated with vehicle (DMSO), 3µM 
sorafenib, 500nM vorinostat or 3µM sorafenib and 500nM vorinostat combined. 48 or 96 h 
after drug treatment, cell viability was measured using the trypan blue exclusion assay. 
One way ANOVA with Bonferroni post-test revealed that sorafenib and vorinostat 
combined induced significantly higher levels of cell death (***, p < 0.001 at 48 h and **, p 
< 0.001 at 96 h, n=6)  as compared to all other treatment conditions. Data (mean ± S.E.M.) 
are from two independent experiments combined. 
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Figure 32: Sorafenib and vorinostat combined enhance cell death in HEPG2 cells. 
12 h after plating HEG2 hepatoma cells, they were treated with vehicle (DMSO), 3µM 
sorafenib, 500nM vorinostat or 3µM sorafenib and 500nM vorinostat combined. 48 or 96 h 
after drug treatment, cell viability was measured using the trypan blue exclusion assay 
±S.E.M. n=2. One way ANOVA with Bonferroni post-test revealed that sorafenib and 
vorinostat combined induced significantly higher levels of cell death (*, p < 0.05 at 48 h 
and ***, p < 0.0001 at 96 h, n=6)  as compared to all other treatment conditions. Data 
(mean ± S.E.M.) are from two independent experiments combined. 
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Figure 33: Knock-down of CD95 protects Panc1 cells from sorafenib+vorinostat 
combined lethality. 12 h after plating Panc1 cells, they were transfected with scrambled 
siRNA (siSCR) or with siRNA to knock-down CD95 (siCD95). 24 h after transfection, 
cells were treated with vehicle (DMSO), 6µM sorafenib, 500nM vorinostat or 3µM 
sorafenib and 500nM vorinostat combined. 48 h after drug treatment, cell viability was 
measured using Trypan blue exclusion assay.  There were significant effects of drug 
treatment and knock-down of CD95 on Panc1 cell death (two-way ANOVA, p<0.0001, 
n=6). Bonferroni’s post-tests revealed that CD95 knock-down significantly protected 
against cell death in the presence of sorafenib and vorinostat combined ( p < 0.001). Data 
(mean ± S.E.M.) are from two independent experiments combined. 
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Figure 34: Over-expression of c-FLIP-s protects Panc1 cells from sorafenib+ 
vorinostat comined lethality. 12 h after plating Panc1 cells, they were infected with an 
empty vector recombinant adenovirus (CMV) or a virus to express c-FLIP-s. 24 h after 
virus infection, cells were treated with vehicle (DMSO), 6µM sorafenib, 500nM vorinostat 
or 6µM sorafenib and 500nM vorinostat combined. 48 h after drug treatment, cell viability 
was measured using trypan blue exclusion assay ±S.E.M. n=2.  There were significant 
effects of drug treatment and FLIP expression on Panc1 cell death (two-way ANOVA, 
p<0.0001, n=6). Bonferroni’s post-tests revealed that FLIP expression significantly 
protected against cell death in the presence of sorafenib or sorafenib and vorinostat 
combined ( p < 0.001). Data (mean ± S.E.M.) are from two independent experiments 
combined. 
 
 
 104
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% apoptotic cells 
CMV
FLIP
Vehicle 6µM Sorafenib 6µM Sorafenib+500nMVorinostat500nM Vorinostat
5.2±0.9 7.8±2.1 6.5±0.4 22.5±5.1
6.1±0.6 7.5±0.3 4.9±0.5 5.6±0.7
 
 
 
 
Figure 35: Panc1 cells over-expressing c-FLIP-s fail to show nuclear fragmentation 
upon sorafenib+vorinostat combined treatment. 12 h after plating Panc1 cells, they 
were treated with vehicle (DMSO), 6µM sorafenib, 500nM vorinostat or 6µM sorafenib 
and 500nM vorinostat combined. 48 h later, cells were fixed and DAPI staining was 
performed using mounting media containing DAPI stain. Apoptosis was measured (50 
cells per condition) by expressing the nuclei with obvious DNA fragmentation as a 
percentage of DAPI positive nuclei (shown below each panel). Representative study 
images from two independent studies shown. 
 
 
 105
 
 
 
 
 
 
 
 
 
 
 
 
 
           
CI For experimental values Hep3B 48h
Sor Valproic Fa CI
(uM) (mM)
2.25 0.75 0.12 0.691
3.00 1.00 0.19 0.687
3.75 1.25 0.36 0.540
 
 
 
Table 2: Sorafenib synergizes with sodium valproate to reduce HEP3B cell survival. 
12h after plating HEP3B hepatoma cells, they were treated with vehicle (VEH, DMSO) or 
sorafenib and sodium valproate, as indicated at a fixed concentration ratio to perform 
median dose effect analyses for the determination of synergy. After drug exposure (48h), 
the media was changed and cells cultured in drug free media for an additional 10-14 days. 
Cells were fixed, stained with crystal violet and colonies of > 50 cells / colony counted. 
Colony formation data were entered into the Calcusyn program and combination index 
(CI) and fraction affected (Fa) values determined. A CI value of less than 1.00 indicates 
synergy and larger the Fa value, the lower the survival under that condition. 
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Figure 36: Sorafenib and sodium valproate combined enhance cell death in Panc1 
cells. 12 h after plating Panc1 cells, they were treated with vehicle (DMSO), 6µM 
sorafenib, 1mM valproate or 6µM sorafenib and 1mM valproate combined. 48 h after drug 
treatment, cell viability was measured using the trypan blue exclusion assay. One way 
ANOVA with Bonferroni post-test revealed that sorafenib and valproate combined induced 
significantly higher levels of cell death (**, p < 0.001, n=6) as compared to all other 
treatment conditions. Data (mean ± S.E.M.) are from two independent experiments 
combined. 
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Figure 37: Sorafenib and sodium valproate combined enhance cell death in HEPG2 
cells.  12 h after plating HEPG2 cells, they were treated with vehicle (DMSO), 3µM 
sorafenib, 1mM sodium valproate or 3µM sorafenib and 1mM sodium valproate combined. 
48h after drug treatment, cell viability was measured using trypan blue exclusion assay. 
One way ANOVA with Bonferroni post-test revealed that sorafenib and valproate 
combined induced significantly higher levels of cell death (***, p < 0.0001, n=6) as 
compared to all other treatment conditions. Data (mean ± S.E.M.) are from two 
independent experiments combined. 
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Figure 38: Mitochondrial translocation of BAX in HEPG2 cells treated with 
sorafenib+ sodium valproate combined. 12 h after plating HEPG2 cells, they were 
treated with vehicle (DMSO) or sorafenib and sodium valproate as indicated. 12 h after 
drug treatment, cell fractionation assay was performed to determine mitochondrial and 
cytosolic localization of BAX. Representative image from two independent studies shown. 
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Figure 39: BAK and BIM co-immunoprecipitation with Mcl-1 in sorafenib+sodium 
valproate combined treated HEPG2 cells. 12 h after plating HEPG2 cells, they were 
treated with vehicle (DMSO) or 3µM sorafenib and 1mM sodium valproate as indicated. 6 
h or 12 h after drug treatment, Mcl-1 was immunoprecipitated and immunoblotting was 
performed to determine levels of BIM or BAK co-immunoprecipitated with Mcl-1. 
Representative image from two independent studies shown.  
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Vehicle 3μM Sorafenib 1mM Valproate 3μM Sorafenib+
1mM Valproate
0.63 88.18±0.74 82.52±1.16 244.8±0.74
Intensity  68.31±
 
 
 
 
 
Figure 40: CD95 cell surface localization in HEPG2 cells treated with sorafenib and 
sodium valproate. 12 h after plating HEPG2 cells, they were treated with vehicle, 
sorafenib, sodium valproate or sorafenib and sodium valproate combined as indicated. 6 h 
post drug treatment, CD95 cell surface localization was performed. Representative images 
from one experiment are shown (n=2). Quantitative assessment of increase in fluorescence 
intensity was determined from fifty cells counted over two independent experiments.  
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Figure 41: Sorafenib dose response in HEPG2 cells with or without obatoclax. 12 h 
after plating HEPG2 cells, they were treated with increasing concentrations of Sorafenib as 
indicated along with Vehicle or 100nM Obatoclax. 48 h after drug treatment, cell viability 
was measured via trypan blue analysis. Two way anova (n=6) shows that there is an effect 
of Sorafenib dose (p < 0.0001) and there is an effect of Obatoclax dose (p < 0.0001). 
Bonferroni post-test shows that the presence of Obatoclax causes a significant increase in 
cell death only under Veh (p < 0.0001) treated or 3 (p < 0.05) and 6 uM (p < 0.0001) 
Sorafenib doses compared to identical conditions in the absence of Obatoclax. Data (mean 
± S.E.M.) are from two independent experiments combined. 
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Figure 42: Vorinostat dose response in HEPG2 cells with or without obatoclax. 12 h 
after plating HEPG2 cells, they were treated with increasing concentrations of Vorinostat 
as indicated along with Vehicle or 100nM Obatoclax. 48 h after drug treatment, cell 
viability was measured via trypan blue analysis. Two way ANOVA (n=6) shows that there 
is an effect of Obatoclax dose (p < 0.0001) but no significant effect of increasing doses of 
Vorinostat on cell death. Bonferroni’s post-test shows that the presence of Obatoclax 
causes a significant increase in cell death under Vehicle treated conditions and also with all 
doses of Valproate (p < 0.0001) compared to identical conditions in the absence of 
Obatoclax. Data (mean ± S.E.M.) are from two independent experiments combined. 
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Figure 43: Sodium valproate dose response in HEPG2 cells with or without obatoclax. 
12 h after plating HEPG2 cells, they were treated with increasing concentrations of sodium 
valproate (VA) as indicated along with vehicle or 100nM obatoclax. 48 h after drug 
treatment, cell viability was measured via trypan blue analysis. Two way ANOVA (n=6) 
shows that there is an effect of obatoclax dose (p < 0.0001) but no significant effect of 
increasing doses of valproate on cell death. Bonferroni’s post-test shows that the presence 
of obatoclax causes a significant increase in cell death under vehicle treated conditions and 
also with all doses of valproate (p < 0.0001) compared to identical conditions in the 
absence of obatoclax. Data (mean ± S.E.M.) are from two independent experiments 
combined. 
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Figure 44: Cell death induced by sorafenib+sodium valproate combined in HEPG2 
cells with or without obatoclax. 12 h after plating HEPG2 cells, they were treated with 
Vehicle (DMSO) or various dose combinations of Sorafenib and Sodium valproate as 
indicated with or without 100nM Obatoclax. 48h after drug treatment, cell viability was 
measured using trypan blue exclusion assay. There were significant effects of sorafenib + 
sodium valproate treatment (at each dose combination tested) and also of obatoclax on 
HEPG2 cell death (two-way ANOVA, p < 0.0001 in both cases, n=6). Bonferroni’s post-
test revealed that the presence of obatoclax significantly enhanced sorafenib + sodium 
valproate induced cell death at each dose combination tested (* p < 0.05, ** p < 0.001, *** 
p < 0.0001). Data (mean ± S.E.M.) are from two independent experiments combined. 
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Figure 45: Knock-down of CD95 failed to protect HEPG2 cells from obatoclax+  
sorafenib+sodium valproate combined lethality. 12 h after plating HEPG2 cells, they 
were transfected with scrambled siRNA (siSCR) or with siRNA to knock-down CD95 
(siCD95). 24 h after being transfected with siRNA, cells were treated with vehicle 
(DMSO), 3µM sorafenib, 1mM valproate or 3µM sorafenib and 1mM valproate combined. 
48 h after drug treatment, cell viability was measured in triplicate using trypan blue 
analysis. There were significant effects of drug treatment and knock-down of CD95 on 
HEPG2 cell death (two-way ANOVA, p<0.0001, n=6). Bonferroni’s post-tests revealed 
that CD95 knock-down significantly protected against cell death in the presence of 
sorafenib and sodium valproate combined or obatoclax (p < 0.001). Data (mean ± S.E.M.) 
are from two independent experiments combined. 
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Figure 46: Over-expression of c-FLIP-s failed to protect HEPG2 cells from 
obatoclax+  sorafenib+sodium valproate combined lethality. 12 h after plating HEPG2 
cells, they were infected with an empty vector recombinant adenovirus (CMV) or a virus to 
express c-FLIP-s. 24 h after virus infection, cells were treated with vehicle (DMSO), 3µM 
sorafenib, 1mM sodium valproate or 3µM sorafenib and 1mM sodium valproate combined. 
48 h after drug treatment, cell viability was measured using trypan blue exclusion assay. 
There were significant effects of drug treatment and FLIP over-expression on HEPG2 cell 
death (two-way ANOVA, p<0.0001, n=6). Bonferroni’s post-tests revealed that FLIP over-
expression significantly protected against cell death in the presence of sorafenib (p < 0.01), 
sorafenib and sodium valproate combined or obatoclax (p < 0.001). Data (mean ± S.E.M.) 
are from two independent experiments combined. 
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Figure 47: Knock-down of Bcl-xl or Bcl-2, but not Mcl-1, enhanced sorafenib+ 
sodium valproate induced cell death. 12 h after plating HEPG2 cells, they were 
transfected with scrambled siRNA (siSCR) or with siRNA to knock-down BclL-xl (siBcl-
xl), Mcl-1 (siMcl-1) or Bcl-2 (siBcl-2). 24 h after transfection, cells were treated with 
vehicle (DMSO) or 3µM sorafenib and 1mM sodium valproate combined. 48 h after drug 
treatment, cell viability was measure using trypan blue assay. One way ANOVA with Bon-
ferroni’s post test showed that knock-down of Bcl-xl or Bcl-2, but not Mcl-1, enhanced 
sorafenib and sodium valproate induced cell death (p < 0.05). Data (mean ± S.E.M.) are 
from two independent experiments combined. 
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Figure 48: Knock-down of Bcl-xl+Bcl-2 or Bcl-xl+Bcl-2+Mcl-1 enhanced sorafenib+ 
sodium valproate induced cell death. 12 h after plating HEPG2 cells, they were 
transfected with control siRNA (siSCR), siRNA to knock-down Bcl-xl+Bcl-2 or Bcl-
xl+Bcl-2+Mcl-1. 24 h later, cells were treated with vehicle (DMSO) or 3µM sorafenib and 
1mM sodium valproate. One way ANOVA with Bon-ferroni’s post test showed that 
knock-down of Bcl-xl+Bcl-2 and of Bcl-xl+Bcl-2+Mcl-1 significantly enhanced sorafenib 
and sodium valproate induced cell death (p < 0.001) compared to siSCR treated cells. Data 
(mean ± S.E.M.) are from two independent experiments combined. 
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Figure 49: BAK and BAX activation in HEPG2 cells treated with sorafenib, sodium 
valproate and obatoclax. 12 h after plating HEPG2 cells, they were treated with vehicle 
(DMSO), 3μM sorafenib and 1mM sodium valproate combined, 250nM obatoclax alone or 
all three drugs combined. 24 h after drug treatment, cells were isolated for 
immunoprecipitation to determine the amount of the activate BAX and BAK. 
Representative images shown (n=2). 
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Figure 50: c-FLIP-s over-expression in HEPG2 cells prevents cytosolic cytochrome c 
release due to sorafenib+sodium valproate+obatoclax. 12 h after plating HEPG2 cells, 
they were treated with vehicle (DMSO), 3μM sorafenib and 1mM sodium valproate 
combined, 250nM obatoclax alone or all three drugs combined. 24 h after drug treatment, 
cells were isolated for cell fractionation assay to determine cytochrome c release into the 
cytosol. A representative from two separate studies is shown. 
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D. Discussion: 
 
We have attempted to determine whether sorafenib and sodium valproate interact to kill 
transformed cells, and whether obatclax mediated inhibition of mitochondrial Bcl-2 family 
protective proteins could enhance sorafenib + sodium valproate toxicity.  
The results of the present study indicate that low concentrations of sorafenib and vorinostat 
as well as sorafenib and sodium valproate interact in a synergistic manner to kill pancreatic 
and liver cancer cells in vitro. Other studies have shown that sorafenib and vorinostat 
combined can induce cell death via ligand independent but ceramide dependent activation 
of the CD95 death receptor signaling pathway (Zhang G, et. al. 2008; Park MA, et. al. 
2008). The CD95 pathway can be negatively regulated by FLIP proteins that have 
sequence homology to caspase 8 but lack the catalytic domain and hence when FLIP is 
recruited to activated death receptors rather than caspases, it can block activation of the 
caspase cascade and the cell death cascade (Krueger A, et. al. 2001). There are several 
splice variants of FLIP known to exist at the mRNA levels but three isoforms of FLIP 
protein namely, c-FLIP-s, c-FLIP-r and c-FLIP-l  have been identified (Djerbi M, et. al. 
2001; Rasper DM, et. al. 1998; Golks A, et. al. 2005). This study confirms that sorafenib + 
vorinostat induced cell death in cancer cells is mediated via CD95 signaling and shows that 
sorafenib + sodium valproate induced lethality in cancer cells also involves CD95 
signaling. Knock-down of CD95 or over-expression of c-FLIP-s protected tumor cells 
from the effects of these drug combinations. Studies have suggested similar roles of c-
FLIP-s and c-FLIP-r in death receptor mediated apoptosis (Golks A, et. al. 2005). We 
chose to over-express c-FLIP-s rather than c-FLIP-l because studies have confirmed the 
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anti-apoptotic role of c-FLIP-s as it can inhibit the activation of pro-caspase 8 and there by 
inhibit CD95 induced cell death (Golks A, et. al. 2005). However, the role of c-FLIP-l in 
the activation of CD95 pathway remains controversial. Some studies suggest the c-FLIP-l 
is an anti-apoptotic molecule where as other studies ascribe pro-apoptotic functions to c-
FLIP-l referring to its assistance in pro-caspase 8 activation (Chang DW, et. al. 2003; 
Micheau O, et. al. 2002). Collectively, the present findings argue that pancreatic and 
hepatoma tumor cells are susceptible to being killed by sorafenib + HDACI exposure 
through a death receptor dependent mechanism. 
Studies have shown that anti-apoptotic Bcl-2 family proteins namely, Bcl-xl and Mcl-1 
play a role in maintaining mitochondrial integrity and prevent activation of cell death 
pathways (Certo M, et. al. 2006; Chipuk JE and Green DR. 2008). In unstressed cells, pro-
apoptotic Bcl-2 family protein BAK has been shown to be sequestered primarily by Mcl-1 
(Cuconati A, et. al. 2003). Upon death receptor and caspase 8 activation, BH-3 only 
protein BID is cleaved to form truncated BID (tBID) which is known to displace BAK 
from the Mcl-1-BAK complex allowing BAK to perform its pro-apoptotic functions 
(Clohessy JG, et. al. 2006). We observed that 6 h after sorafenib and sodium valproate 
treatment, no significant change in Mcl-1 level is observed compared to control treated 
cells. However, at this time point after sorafenib and sodium valproate combined 
treatment, a decrease in BAK association with Mcl-1 is observed suggesting that BAK is 
available to activate cell death pathways as early as 6 h post sorafenib and sodium 
valproate combined treatment. 12 h post sorafenib and sodium valproate treatment, a 
decrease in Mcl-1 level as well as a decrease in BIM co-immunoprecipitated with Mcl-1 in 
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observed. Studies have shown that in unstressed cells, BIM is sequestered by Mcl-1 and 
certain stressful stimuli can lead to caspase mediated degradation of Mcl-1 and this allows 
Mcl-1-free BIM to initiate cell death pathways (Han J, et. al. 2006). 
It is known that the pro-apoptotic Bcl-2 family protein BAX primarily resides in the 
cytosol of unstressed cells and upon certain stressful stimuli, BAX is known to translocate 
to the mitochondria where it can damage mitochondrial integrity and initiate cell death 
pathways (Murphy KM, et. al. 2000). We found that sorafenib and sodium valproate 
combined induce mitochondrial localization of BAX within 12 h of treatment suggesting 
that upon exposure to the drug combination, BAX translocates to the mitochondria in order 
to initiate cell death pathways.  
Studies have shown that in cancer cells HDACI alone can induce CD95 activation and 
sorafenib and vorinostat combined can cause an increase in CD95 cell surface 
localization/activation 6 h post drug treatment (Insinga A, et. al. 2005; Zhang G, et. al. 
2008). Our results showed that 6 h after drug treatment, neither sorafenib nor sodium 
valproate alone induced CD95 cell surface localization but this was observed in cells 
treated with both drugs at the same time suggesting that the drug combination is able to 
activate CD95 cell death pathway as early as 6 h after treatment. This also indicates that 
CD95 activation is likely invovled in mediating cell death induced by sorafenib and 
sodium valproate combination treatment. 
An inability to express death receptors or the ability to over-express dominant negative 
forms of death receptors has been linked to apoptosis resistance (Walsh CM, et. al. 2003; 
Safa AR, et. al. 2008). An additional mechanism that could block toxic death receptor 
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signaling is constitutive high expression levels of c-FLIP-s (Safa AR, et. al. 2008). 
Increased expression of mitochondrial protective proteins such as Mcl-1 and Bcl-xl have 
also been implicated in mediating drug resistance in cancer cells (Martin AP, et. al. 2008; 
Del Poeta G, et. al. 2008). As mentioned previously, our studies show that sorafenib + 
HDACI combined can trigger cell death via CD95 signaling. We wanted to enhance the 
toxicity of sorafenib and sodium valproate combined, as well as reduce the chance of 
resistance development in cancer cells treated with these agents. Therefore, it was logical 
to combine sorafenib and sodium valproate with obatoclax, which can facilitate cell death 
independent of CD95 signaling, target the mitochondrial protective proteins, and according 
to our results, obatoclax can enhance cell death in cancer cells when combined with 
sorafenib and sodium valproate at all dose combinations tested. Theoretically, using these 
three drugs in combination would reduce the likelihood of tumor cells being resistant as 
well as potentially circumventing the development of drug resistant cancers. We found that 
while knock-down of CD95 or over-expression of c-FLIP-s, protected tumor cells from 
sorafenib and sodium valproate combined lethality, additional treatment of cells with 
obatoclax under these conditions failed to protect them from cell death. This confirmed our 
hypothesis that treating cancer cells with obatoclax+sorafenib+sodium valproate induces 
cell death that is maintained even upon blockade of CD95 signaling.  
No significant effect on cell death was found upon addition of obatoclax to cells co-treated 
with varying doses of vorinostat or sodium valproate. The presence of obatoclax, however, 
caused a significant increase in cell death when combined with 3 uM and 6 uM sorafenib 
compared to identical conditions in the absence of obatoclax. However, cell death was 
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enhanced most when obatoclax was combined with sorafenib and sodium valproate 
simultaneously.  
As mentioned previously, obatoclax is a pan-inhibitor of the protective Bcl-2 family 
proteins which includes Bcl-xl, Mcl-1 and Bcl-2 (Trudel S, et. al. 2007). Since obatoclax 
enhanced sorafenib and sodium valproate mediated cell death, we determined whether 
knock-down of Bcl-xl, Mcl-1 or Bcl-2 alone would be sufficient to mimic the effects of 
obatoclax on sorafenib and sodium valproate treated cells. siRNA mediated individual 
knock-down of Bcl-xl or Bcl-2 , but not Mcl-1, significantly enhance sorafenib and sodium 
valproate induced cell death compared to control siRNA treated cells. Simultaneous knock 
down of Bcl-2 and Bcl-xl significantly increased sorafenib + sodium valproate toxicity 
compared to control siRNA treated cells. Furthemore, simultaneous loss of Bcl-2, Bcl-xl 
and Mcl-1 expression resulted in a significant increase in sorafenib + sodium valproate 
induced cell death compared to control siRNA and siBcl-xl + siBcl-2 treated cells. This 
suggests that inhibiting more than one pro-survival Bcl-2 family protein at the same time, 
rather than individual Bcl-2 family members, enhances sorafenib and sodium valproate 
mediated lethality to a greater extent.  
Studies have shown that in the presence of cellular stress, BAK and BAX change 
conformation, oligomerize and form pores in the outer mitochondrial membrane that 
allows the release of proteins from the inter-mitochondrial space that can then activate cell 
death pathways (Antignani A and Youle RJ. 2006). Immunoblotting studies showed that 
compared to vehicle conditions, treatment of cells with sorafenib + sodium valproate 
combined, obatoclax alone or sorafenib + sodium valproate + obatoclax combined resulted 
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in increased “active” BAK and BAX proteins suggesting that in the presence of the above 
mentioned drug treatments, BAK and BAX are activated and hence available to initiate cell 
death pathways. 
Upon activation, pro-apoptotic Bcl-2 family proteins BAK and BAX can lead to the 
release of cytochrome c from the mitochondria to cytosol (Wei MC, et. al. 2001; Desagher 
S, et. al. 1999). This is considered a key step in the initiation of cell death pathways as this 
can lead to formation of the apoptosome consisting of cytochrome c, its adaptor molecule 
called Apaf-1 (apoptotic protease activating factor 1) and pro-caspase 9 (Cain K, et. al. 
2000). Binding of cytochrome c to Apaf-1 is thought to facilitate the binding of ATP to the 
apoptosome which then allows for caspase 9 activation (Adrain C, et. al. 1999). Active 
caspase 9 can then lead to activation of various other caspases including caspase 2, 3, 6, 7, 
8 and 10 (Guerrero AD, et. al. 2008).Cells treated with sorafenib + sodium valproate + 
obatoclax simultaneously show a higher level of cytochrome c release into the cytosol as 
compared to other treatment conditions. Over-expression of c-FLIP-s abolishes basal and 
sorafenib + sodium valproate induced cytosolic release of cytochrome c. However, in spite 
of c-FLIP-s over-expression, cytosolic release of cytochrome c is observed in cells treated 
with either obatoclax alone or treated with sorafenib + sodium valproate + obatoclax 
combined. This indicates that cell death pathways can be activated via cytosolic release of 
cytochrome c in cells treated with sorafenib + sodium valproate + obatoclax in spite of loss 
of CD95 function mediated by c-FLIP-s over-expression.  
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As sorafenib+HDACI therapy is about to be explored in a phase I trial, our data suggest 
that the incorporation of obatoclax together with sorafenib+HDACI therapy may provide 
significant additional value in tumor control.           
In conclusion, the results of the present study indicate that sorafenib and vorinostat or 
sodium valproate interact in a synergistic manner to kill pancreatic and liver tumor cells in 
vitro via activation of CD95. These effects are magnified when Bcl-2 family protein 
activity is inhibited and of novelty demonstrate that loss of extrinsic pathway activation 
does not diminish cell death levels induced by sorafenib and sodium valproate in 
combination with obatoclax.  
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GENERAL DISCUSSION 
 
We investigated the mechanism of lapatinib mediated cell death and lapatinib resistance in 
HCT 116 colon cancer cells. Lapatinib has been approved by the Food and Drug 
Administration to be used in the treatment for breast cancer as part of a combination 
therapy. Clinical trials have been planned and are underway to investigate the use of 
lapatinib in the treatment of other types of cancers including colorectal cancer 
(Clinicaltrials.gov). Hence, it is important to understand the mechanism of action of 
lapatinib in order to optimize its toxic effects on cancer cells and also identify other drugs 
that may be combined with lapatinib to enhance cancer cell killing and reduce occurrence 
of refractory cancers. Lapatinib has been known to cause its effects by inhibiting ERBB1 
and ERBB2 tyrosine kinase receptors and their downstream signaling pathways (Wood 
ER, et. al. 2004; Rusnak DW, et. al. 2001). We expressed dominant negative ERBB1 
and/or ERBB2 receptors in wild-type HCT116 colon cancer cells in order to mimic the 
effects of lapatinib and to investigate whether inhibition of these receptors was the sole 
mechanism of lapatinib mediated toxicity in these cells. Dominant negative ERBB1 and 
ERBB2 receptors were able to inhibit receptor activation similar to lapatinib but were 
unable to induce comparable levels of cell death as seen in the presence of lapatinib. It is 
possible that CD533 and CD572 inhibit the receptors but are unable to inhibit downstream 
ERK and Akt activation Hence, we determined whether an inability to inhibit ERK1/2 and 
Akt pro-survival signaling pathways prevented CD533 and CD572 from inducing of cell 
death in WT cells. However, dominant negative ERBB1 and ERBB2 receptors inhibited 
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ERK1/2 and Akt phosphorylation in WT cells indicating that lack of inhibition of these 
pro-survival signaling pathways was not the reason for lack of cell death in cells treated 
with CD533 and CD572. This data suggests that lapatinib mediated effects in wild-type 
HCT 116 cells may not solely depend on inhibition of ERBB1 and ERBB2 pathways and 
that possibly other targets of lapatinib are involved. Several drugs have been developed to 
target specific, however, over the years, studies have shown that these agents can mediate 
their toxicity by inhibition of other target molecules as well. For instance, sorafenib was 
developed as a Raf-kinase inhibitor but later studies showed that it could mediate its 
effects via inhibition of other kinases such as VEGFR and PDGFR (Wilhelm SM, et. al. 
2008). Hence, it is possible that further studies may reveal other targets of lapatinib. 
The present study showed that lapatinib induced cell death in wild-type HCT 116 cells is 
caspase independent and is mediated by cytosolic release of apoptosis inducing factor 
(AIF) from the mitochondria which is thought to initiate cell death (Penninger JM and 
Kroemer G. 2003). Other chemotherapeutic agents have also been known to induce cell 
death via AIF activation. For instance, studies show that arsenic trioxide is effective in 
killing human cervical cancer cells via cytosolic release of AIF (Kang YH, et. al. 2004).  
Chemotherapeutic drug resistance development has been shown to be a major problem in 
the process of treating cancer (Kobayashi S, et. al. 2005). Initial drug treatment may kill 
cancer cells but often times cells may become resistant to drugs used to treat the cancer 
initially and also to a variety of other chemotherapeutic agents making it refractory cancers 
very difficult to manage (Kobayashi S, et. al. 2005). Our studies show that it is possible for 
lapatinib resistance to occur in colon cancer cells. This suggests that lapatinib resistance 
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could occur in patients and understanding the mechanism of lapatinib resistance in colon 
cancer cells may enable us to diagnose and treat resistance development in the clinic. It 
may also assist us in designing combinatorial therapy regimes in order to reduce the 
chances of lapatinib resistance development in cancer patients.  
Other studies have shown that in breast cancer cells, lapatinib resistance can occur due 
alterations in the PI3K pathway via loss-of-function mutations in the tumor suppressor 
PTEN, up-regulation of estrogen receptor or due to an inabililty of lapatinib to inhibit pro-
survival ERK and Akt signaling downstream of ERBB receptors (Eichhorn PJ, et. al. 2008; 
Chen FL, et. al. 2008; Zhou H, et. al. 2004). However, in WT-AD cells, it was observed 
that inhibition estrogen receptor signaling did not restore lapatinib sensitivity in these cells 
suggesting that lapatinib resistance in WT-AD cells was unlikely to be mediated by 
changes in estrogen receptor signaling. Studies performed by others in our laboratory have 
also shown that inhibition of ERK1/2 and/or Akt in WT-AD cells did not enhance lapatinib 
mediated cell death suggesting that these proteins were not responsible for lapatinib 
resistance in WT-AD cells (Martin AP, et. al. 2008).  
In WT-AD cells, increased expression Bcl-xl, Mcl-1 and p53 proteins, decreased 
expression of pro-death Bax protein and decreased phosphorylation of p53 was noted. It 
was also found that Bax and Bak proteins were activated in lapatinib treated wild-type 
HCT 116 cells but not in WT-AD cells. Hence, it appears that alterations in the expression 
and activation of Bcl-2 family proteins are involved in mediating lapatinib resistance in 
HCT 116 colon cancer cells. Other studies have shown that altered expression of Bcl-2 
family proteins can confer multi-drug resistance phenotype in cancer cells by dramatically 
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reducing toxicity mediated by commonly used therapeutic agents such as bleomycin, 
cisplatin and etoposide (Raffo AJ, et. al. 1995; Minn AJ, et. al. 1995). Hence, several 
drugs have been developed to target Bcl-2 family proteins such as obatoclax that mimics 
the BH-3 domain of pro-death Bcl-2 family members and can inhibit the activity of pro-
survival Bcl-2 members by interacting with them (Zhang L, et. al. 2007).  
Further studies will be required to investigate the effects of Bcl-2 family inhibitors on WT 
and WT-AD cells but it can be expected that such inhibitors will prove to be toxic to 
lapatinib resistant WT-AD cells. If this is the case, it may prove beneficial to combine 
lapatinib with a Bcl-2 family inhibitor such as obatoclax in the clinic in order to reduce the 
likelihood of resistance development in patients. 
Our studies confirmed previous finding that multi-kinase inhibitor sorafenib and vorinostat 
(a histone deacetylase inhibitor or HDACI) combined toxicity is mediated via CD95 death 
receptor pathway (Zhang G, et. al. 2008; Park MA, et. al. 2008). We have also shown that 
sorafenib interacts with another HDACI named sodium valproate in a synergistic manner 
to kill transformed cells via a mechanism involving the CD95 death receptor pathway.  
Studies have shown that HDACIs themselves can cause an induction of the CD95/CD95L 
system and hence cells treated with HDACI alone may also show elevated CD95 surface 
localization/activation (Glick RD, et. al. 1999). However, at the time-points tested, we 
found that CD95 cell surface localization was elevated in cells treated with sorafenib and 
sodium valproate combined but not in cells treated with vehicle or individual drugs.  
Previous studies have shown that in cancer cells, resistance to drugs that mediate their 
effects via the CD95 pathway can occur due to an inability of the cells to express death 
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receptors or by over-expressing dominant negative forms of death receptors (Park SM, et. 
al. 2005; Walsh CM, et. al. 2003). Since sorafenib+HDACI mediated effects involve 
CD95 activation, it is possible that alterations in the CD95 signaling pathway may render 
cancer cells resistant to this drug combination. Hence, we wanted to combine sorafenib and 
sodium valproate with a third agent i.e. obatoclax. Obatoclax mediated cell death is CD95 
independent and therefore combining it with sorafenib+sodium valproate may reduce 
chances of resistance development occurring due to alterations in the CD95 signaling 
pathway. Obatoclax is a BH-3 mimetic and binds the BH-3 binding domain of the Bcl-2 
family proteins and is known to mediate its effects in cancer cells via inhibition of Mcl-1-
BAK interaction, BIM upregulation and cytochrome c release into the cytosol (Trudel S, 
et. al. 2007). Alterations in the Bcl-2 family proteins have also been implicated in 
mediating chemotherapeutic drug resistance in cancer (Martin AP, et. al. 2008) and based 
on previous, using obatoclax may likely reduce occurrence of resistance development in 
cancer cells via alterations in the Bcl-2 family proteins as well (Nguyen M, et. al. 2007).  
Results showed that obatoclax enhanced the toxicity of sorafenib and sodium valproate 
combined. Knock-down of CD95 or over-expression of c-FLIP-s (a negative regulator of 
the CD95 pathway) to mimic a non-functional CD95 pathway, protected cells from 
sorafenib+sodium valproate mediated cells death. However, no significant reduction in cell 
death levels was found in HEPG2 hepatoma cells treated with all three agents (i.e. 
sorafenib+sodium valproate+obatoclax) in spite of CD95 knock-down or over-expression 
of c-FLIP-s. This confirmed our hypothesis that combining sorafenib and sodium valproate 
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with obatoclax (which is known to mediate cell death independent of CD95 activation) 
maintains toxic effects in cancer cells even if the CD95 pathway is not functional.  
In conclusion, the results of the present study indicate that sorafenib and vorinostat or 
sodium valproate interact in a highly synergistic manner to kill tumor cells in vitro via 
activation of CD95 pathway. These effects are magnified as well as maintained in spite of 
loss of CD95 death receptor pathway function when Bcl-2 family protein activity is 
inhibited in addition to sorafenib+sodium valproate treatment of HEPG2 liver cancer cells. 
This suggests that it may prove beneficial to combined sorafenib+HDACI with a Bcl-2 
family inhibitor such as obatoclax in order to avoid occurrence of refractory cancers in 
patients.  
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